



## (51) International Patent Classification:

G01N 33/68 (2006.01) G06F 19/10 (2011.01)  
G01N 33/50 (2006.01) A61K 39/00 (2006.01)  
G01N 33/574 (2006.01) C12Q 1/68 (2006.01)

## (21) International Application Number:

PCT/US2016/052487

## (22) International Filing Date:

19 September 2016 (19.09.2016)

## (25) Filing Language:

English

## (26) Publication Language:

English

## (30) Priority Data:

62/220,884 18 September 2015 (18.09.2015) US

(71) Applicant: BAYLOR COLLEGE OF MEDICINE  
[US/US]; One Baylor Plaza, Houston, TX 77030-3411 (US).

## (72) Inventors: LEEN, Ann, Marie; 5227 Maple Street, Bellaire, TX 77401 (US). AGUAYO-HIRALDO, Pailbel; Mail Stop: BM210-One Baylor Plaza, Houston, TX 77030-

3411 (US). TZANNOU, Ifigeneia; Mail Stop: BM210-One Baylor Plaza, Houston, TX 77030-3411 (US). VERA, Juan, F., Valdes; 5227 Maple Street, Bellaire, TX 77401 (US).

## (74) Agents: SISTRUNK, Melissa, L. et al.; Norton Rose Fulbright US LLP, 1301 McKinney, Suite 5100, Houston, TX 77010-3095 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH,

[Continued on next page]

## (54) Title: IMMUNOGENIC ANTIGEN IDENTIFICATION FROM A PATHOGEN AND CORRELATION TO CLINICAL EFFICACY




FIG. 1

(57) Abstract: Embodiments of the disclosure concern methods of identifying whether or not antigens from a particular pathogen are immunogenic, including the order of their immunogenicity. Other embodiments concern correlations between attributes of T cells and their clinical efficacy, such as mathematical representations thereof.



GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,  
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,  
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,  
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,  
LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE,

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA,  
GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Published:**

— *with international search report (Art. 21(3))*

## IMMUNOGENIC ANTIGEN IDENTIFICATION FROM A PATHOGEN AND CORRELATION TO CLINICAL EFFICACY

**[0001]** This application claims priority to U.S. Provisional Patent Application Serial No. 62/220,884, filed September 18, 2015, which is incorporated by reference herein in its entirety.

### TECHNICAL FIELD

**[0002]** Embodiments of the disclosure concern at least the fields of cell biology, molecular biology, immunology, and medicine.

### BACKGROUND

**[0003]** Hematopoietic stem cell transplant (HSCT) is the treatment of choice for a variety of malignant and non-malignant disorders. Post-transplant, however, graft versus host disease (GVHD), primary disease relapse and viral infections remain major causes of morbidity and mortality. Viral infections are detected in the majority of allograft recipients. Although available for some viruses, antiviral drugs are not always effective, highlighting the need for novel therapies. One strategy to treat these viral infections is with adoptive T cell transfer, including at least infusion of donor-derived virus-specific T cells (VSTs), for example. With a VST approach, one can extract cells from a donor, expand virus-specific populations *ex vivo* and, finally, infuse the T cell product into the stem cell transplant recipient, for example.

**[0004]** *In vitro* expanded donor-derived and 3<sup>rd</sup> party VSTs targeting Adv, EBV, CMV, BK, HHV6 have shown to be safe when adoptively transferred to stem cell transplant patients with viral infections. VSTs reconstituted antiviral immunity for Adv, EBV, CMV, BK and HHV6, were effective in clearing disease, and exhibited considerable expansion *in vivo*. Adoptively transferred *in vitro* expanded autologous cancer-specific T cells have also been shown to be safe and associated with clinical benefit when adoptively transferred to patients.

**[0005]** Embodiments of the present disclosure satisfy a long-felt need in the art by providing therapies for certain pathogens and cancer antigens, and also for identifying which antigens are immunogenic and clinically efficacious.

## BRIEF SUMMARY

**[0006]** Embodiments of the disclosure concern methods, compositions, and/or systems for generating immunotherapies, including for identifying one or more antigen(s) that would be clinically efficacious in one or more immunotherapies for a mammalian individual, such as a human or a dog. Embodiments of the methods concern determining which antigens from a pathogen or cancer cell are suitably immunogenic to be utilized for one or more therapeutic applications in a mammal. In certain embodiments the pathogen is a virus, bacteria, or fungi, for example.

**[0007]** In particular embodiments, methods of the disclosure concern the determination of the immunogenicity for a plurality of antigens from a pathogen and/or cancer cell in question and concern an ordering of the immunogenicity based on a suitable biological determination. The determination of a hierarchy of the antigens based on their immunogenicity can be utilized in considering a suitable immunogenic therapy for an individual that has the pathogen or cancer and that is susceptible or at risk for exposure and/or disease from the pathogen and/or cancer. In specific embodiments, the suitable immunogenic therapy comprises the most suitable immunogenic therapy based on the immunodominance of antigens for a particular pathogen or cancer.

**[0008]** In various embodiments at least two antigens from a pathogen or cancer are identified and their level of immunogenicity is quantitated. The antigens can then be ranked in order based upon their level of immunogenicity so that a determination can be made as to which of the antigens should be used a target for an immunotherapy.

**[0009]** The immunogenic therapy designed based on the determination of the hierarchy of antigens may be of any kind, but in specific embodiments the immunogenic therapy comprises vaccines, adoptive cell therapy, monoclonal antibody, bi-specific antibodies (BITES), oncolytic virus, or a combination thereof. The immunotherapy may comprise adoptive T cell therapy (native T cell receptor (TCR), engineered TCRs, or CAR T cells), although other types of immune cells may be utilized, including NK cells, NK T cells, mesenchymal stromal cells (MSCs), and dendritic cells (DC). The immunotherapy may rely on the production and use of immune cells including those that rely on T cell receptors that are native or engineered and those that rely on NK cells, NKT cells, mesenchymal stromal cells (MSCs), and dendritic cells (DCs). For example, a T cell therapy can be designed that attacks at least two of most immunogenic

antigens of a pathogen or cancer with the intent of destroying a respective pathogenic cell or a cancer cell. Such a therapy could include a T cell manufacturing process that generates T cells that are able to recognize at least two of the most immunogenic antigen targets from a pathogen or cancer. In alternative embodiments, the T cell therapy targets only one antigen from a pathogen or cancer.

**[0010]** In certain embodiments, the immunogenicity of more than one antigen from a pathogen or a cancer is determined and is ordered into a hierarchy for use in considering the one or more antigens to be utilized in therapy for an individual that has been exposed to the pathogen (including has contracted a disease caused directly or indirectly by the pathogen), or may be exposed to the pathogen, or who has cancer or is at risk of developing cancer, or as a result of being exposed to the pathogen is at risk of developing cancer.

**[0011]** In specific embodiments, evaluations are undertaken to build an information base that can be used to assign a value to the level of immunogenicity of a given antigen. The information base is established as follows: a) peripheral blood mononuclear cells (PBMCs), obtained from pathogen exposed individuals or cancer patients, undergo an in vitro culture process that exposes the PBMCs to two or more antigens from the pathogen or two or more antigens from the cancer, preferably in the presence of Th-1 polarizing cytokines; b) a period of time is allowed to let T cells that recognize the antigens multiply in quantity; c) the culture is split into as many separate cultures as the number of antigens that were present in step a and only one of the antigens is added into each culture, each culture thereby including one of the original antigens and each culture including an antigen that differs from the other cultures; d) biological activity is measured (which may be referred to as a biological measurement); e) either in parallel or at a different time, perhaps becoming a historic reference, a threshold for biological activity is established by an in vitro assessment of the biological activity occurring in PBMCs that have not been exposed sequentially or in parallel in vitro to the same agent(s) of step c; f) the biological activity of each of the cultures of step c is compared to the threshold and those that have biological activity that exceeds the threshold are classified as responders and those that do not have biological activity that exceeds the threshold are classified as non-responders and g) as a result of steps a-f the frequency of responders and non-responders relative to the number individuals evaluated is known and the magnitude of the responders biological activity relative to the threshold and relative to zero is known.

**[0012]** Skilled artisans recognize that in specific aspects a threshold is the noise in the process of measuring biological activity. There is more than one way to establish the threshold. For example, as described above, PBMCs can be exposed to each antigen used in the process and the subsequent biological activity can be measured to establish the threshold. Alternatively for example, the cultures of step c can also be challenged with an antigen that is not included in step a. Both approaches will detect noise and thereby establish the threshold that needs to be exceeded for the culture that is exposed to the antigen of interest to be classified as a responder.

**[0013]** In certain embodiments, there is a method of characterizing immunogenic antigens for a pathogen or cancer, comprising the steps of providing or generating multiple pluralities of T cells, wherein each plurality of T cells is specific for one antigen from the pathogen or cancer; assaying for a quantifiable biological response from cells from each plurality upon challenge from their respective antigens, wherein a quantitated output of the biological response is measured against a threshold quantity to determine the efficacy and magnitude of the response from each plurality, wherein the efficacy is the percentage of individuals in a population that have a biological response that exceeds the threshold quantity; and ordering the immunogenicity of each antigen based on a mathematical relationship between the efficacy and magnitude of the response from each plurality.

**[0014]** In other embodiments, a formula is established that uses variables including the percentage of responders and the percentage of non-responders as well as the magnitude of the biological response to assign a value to an antigen, the higher the value the higher the level of immunogenicity assigned to a particular antigen.

**[0015]** In other embodiments, a formula is established that uses variables including the percentage of responders and the percentage of non-responders as well as the magnitude of the biological response to assign a value to an antigen, the higher the value the higher the level of immunogenicity assigned to a particular antigen.

**[0016]** Provided herein are examples of methods of immune profiling of exemplary Virus X, Bacteria Y, Tumor Z and also of specific but exemplary viruses, such as parainfluenza type III (PIV3) and human Metapneumovirus (hMPV). In specific embodiments, the immunogenicity of multiple antigens for PIV3 and hMPV are respectively determined and utilized in therapy.

**[0017]** In particular embodiments, the methods and compositions of the disclosure concern adoptive T-cell therapy to prevent or treat infection. such as following HSCT. In particular cases, the disclosure includes therapy for the prevention or treatment of viral infection, including at least for infection by PIV (including at least PIV3), hMPV, cytomegalovirus, BK virus, human herpesvirus 6, adenovirus, Epstein Barr virus, BK virus, RSV, Influenza, Parainfluenza, Bocavirus, Coronavirus, LCMV, Mumps, Measles, Metapneumovirus, Parvovirus B, Rotavirus, West Nile Virus, JC, or HHV7, for example. Viruses from any viral infection may be treated, including from one of the following families: *Adenoviridae*, *Picornaviridae*, *Herpesviridae*, *Hepadnaviridae*, *Flaviviridae*, *Retroviridae*, *Orthomyxoviridae*, *Paramyxoviridae*, *Papovaviridae*, *Polyomavirus*, *Rhabdoviridae*, or *Togaviridae*.

**[0018]** Bacteria that may comprise the pathogen of interest include at least the following: *Bacillus anthracis*, *Bacillus cereus*, *Bartonella henselae*, *Bartonella Quintana*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Borrelia garinii*, *Borrelia afzelii*, *Borrelia recurrentis*, *Brucella abortus*, *Brucella canis*, *Brucella melitensis*, *Brucella suis*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Chlamydophila psittaci*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Clostridium tetani*, *Corynebacterium diphtheria*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Francisella tularensis*, *Haemophilus influenza*, *Helicobacter pylori*, *Legionella pneumophila*, *Leptospira interrogans*, *Leptospira santarosai*, *Leptospira weilii*, *Leptospira noguchii*, *Listeria monocytogenes*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycobacterium ulcerans*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitides*, *Pseudomonas aeruginosa*, *Rickettsia rickettsii*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus saprophyticus*, *Streptococcus agalactiae*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Yersinia pestis*, *Yersinia enterocolitica*, or *Yersinia pseudotuberculosis*, for example.

**[0019]** In particular embodiments, the methods and compositions of the disclosure also concern adoptive T-cell therapy to prevent or treat cancer, including cancer that is selected from the group consisting of Acute Lymphoblastic Leukemia (ALL), acute Myeloid Leukemia (AML), Adrenocortical Carcinoma, Adrenal Cortex Cancer, AIDS-Related Cancers, Kaposi Sarcoma, AIDS-Related Lymphoma, Primary CNS Lymphoma, Anal Cancer, Appendix Cancer, Astrocytomas, Atypical Teratoid/Rhabdoid Tumor, Basal Cell Carcinoma, Bile Duct Cancer,

Bladder Cancer, Bone Cancer (including Ewing Sarcoma and Osteosarcoma and Malignant Fibrous Histiocytoma), Breast Cancer, Bronchial Tumors, Burkitt Lymphoma, Gastrointestinal Carcinoid Tumor, Carcinoid Tumors, Cardiac (Heart) Tumors, Embryonal Tumors, Germ Cell Tumors, Lymphoma, Cervical Cancer, Cholangiocarcinoma, Chordoma, Chronic Lymphocytic Leukemia (CLL), Chronic Myelogenous Leukemia (CML), Chronic Myeloproliferative Neoplasms, Colorectal Cancer, Craniopharyngioma, Cutaneous T-Cell Lymphoma, Ductal Carcinoma In Situ (DCIS), Embryonal Tumors, Endometrial Cancer, Ependymoma, Esophageal, Esthesioneuroblastoma, Extracranial Germ Cell Tumor, Extragonadal Germ Cell Tumor, Fallopian Tube Cancer, Fibrous Histiocytoma of Bone, Malignant, and Osteosarcoma, Gallbladder Cancer, Gastric (Stomach) Cancer, Gastrointestinal Carcinoid Tumor, Gastrointestinal Stromal Tumors (GIST), Extracranial Germ Cell Tumor, Extragonadal Germ Cell Tumor, Ovarian Cancer, Testicular Cancer, Gestational Trophoblastic Disease Gliomas, Hairy Cell Leukemia, Head and Neck Cancers, Heart Tumors, Hepatocellular Cancer, Langerhans Cell Histiocytosis, Hodgkin Lymphoma, Hypopharyngeal Cancer, Intraocular Melanoma, Islet Cell Tumors, Pancreatic Neuroendocrine Tumors, Pancreatic Cancer, Kaposi Sarcoma, Laryngeal Cancer, Laryngeal Papillomatosis, Leukemia, Lip and Oral Cavity Cancer, Liver Cancer, Lung Cancer, Non-Hodgkin Lymphoma, Malignant Fibrous Histiocytoma of Bone, Osteosarcoma, Melanoma, Intraocular Melanoma, Merkel Cell Carcinoma, Skin Cancer, Mesothelioma, Malignant Mesothelioma, Metastatic Squamous Neck Cancer with Occult Primary, Midline Tract Carcinoma Involving NUT Gene, Mouth Cancer - Head and Neck Cancer, Multiple Endocrine Neoplasia Syndromes, Multiple Myeloma/Plasma Cell Neoplasms, Mycosis Fungoides, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Chronic Myeloproliferative Neoplasms, Myelogenous Leukemia, Chronic (CML), Nasal Cavity and Paranasal Sinus Cancer, Nasopharyngeal Cancer, Neuroblastoma, Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Oral Cancer, Lip and Oral Cavity Cancer, Oropharyngeal Cancer, Oral Cavity Cancer, Osteosarcoma, Pancreatic Cancer, Papillomatosis, Paraganglioma, Paranasal Sinus and Nasal Cavity Cancer, Parathyroid Cancer, Penile Cancer, Pharyngeal Cancer, Pheochromocytoma, Pituitary Tumor, Plasma Cell Neoplasm/Multiple Myeloma, Pleuropulmonary Blastoma, Primary Central Nervous System (CNS) Lymphoma, Peritoneal Cancer, Prostate Cancer, Rectal Cancer, Colorectal Cancer, Renal Cell (Kidney) Cancer, Retinoblastoma, Rhabdomyosarcoma, Salivary Gland Cancer, Salivary Gland Tumors, Sarcoma, Osteosarcoma, Rhabdomyosarcoma, Uterine Sarcoma, Uterine Cancer, Vascular Tumors, Sézary Syndrome, Skin Cancer, Small Cell Lung Cancer, Small Intestine Cancer, Soft



Tissue Sarcoma, Squamous Cell Carcinoma, Squamous Neck Cancer, Stomach (Gastric) Cancer, Cutaneous T-Cell Lymphoma, Testicular Cancer, Throat Cancer, Thymoma, Thymic Carcinoma, Thyroid Cancer, Thyroid Tumors, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer, Uterine Cancer, Endometrial, Uterine Sarcoma, Vaginal Cancer, Vascular Tumors, Vulvar Cancer, Waldenström Macroglobulinemia (Non-Hodgkin Lymphoma) and Wilms Tumor.

**[0020]** Other and further objects, features, and advantages would be apparent and eventually more readily understood by reading the following specification and be reference to the accompanying drawings forming a part thereof, or any examples of the presently preferred embodiments of the invention given for the purpose of the disclosure.

#### BRIEF DESCRIPTION OF THE DRAWINGS

**[0021]** FIG. 1 illustrates an example of immunogenic antigen identification for an exemplary Virus X including exposing PBMCs to multiple antigens followed by re-challenge and determination of a threshold and identification of responders and non-responders.

**[0022]** FIG. 2 provides an example of a mathematical formula for ordering the immunogenicity of each antigen in FIG. 1 and identification of an antigen hierarchy.

**[0023]** FIG. 3 shows one example of selection of specific antigens based on the antigen hierarchy in FIG. 2.

**[0024]** FIG. 4 shows one example of selection of specific antigens based on the antigen hierarchy in FIG. 2.

**[0025]** FIG. 5 shows one example of selection of specific antigens based on the antigen hierarchy in FIG. 2.

**[0026]** FIG. 6 illustrates an example of immunogenic antigen identification for an exemplary Bacteria Y including exposing PBMCs to multiple antigens followed by re-challenge and determination of a threshold and identification of responders and non-responders.

**[0027]** FIG. 7 provides an example of a mathematical formula for ordering the immunogenicity of each antigen in FIG. 6 and identification of an antigen hierarchy.

**[0028]** FIG. 8 shows one example of selection of specific antigens based on the antigen hierarchy in FIG. 7.

**[0029]** FIG. 9 shows one example of selection of specific antigens based on the antigen hierarchy in FIG. 7.

**[0030]** FIG. 10 shows one example of selection of specific antigens based on the antigen hierarchy in FIG. 7.

**[0031]** FIG. 11 illustrates an example of immunogenic antigen identification for an exemplary Tumor Z including exposing PBMCs to multiple antigens followed by re-challenge and determination of a threshold and identification of responders and non-responders.

**[0032]** FIG. 12 provides an example of a mathematical formula for ordering the immunogenicity of each antigen in FIG. 11 and identification of an antigen hierarchy.

**[0033]** FIG. 13 shows one example of selection of specific antigens based on the antigen hierarchy in FIG. 12.

**[0034]** FIG. 14 shows one example of selection of specific antigens based on the antigen hierarchy in FIG. 12.

**[0035]** FIG. 15 shows one example of selection of specific antigens based on the antigen hierarchy in FIG. 12.

**[0036]** FIG. 16 illustrates a HMPV molecule and its gene products, including 3'-N-P-M-F-M2-SH-G-L-5'.

**[0037]** FIG. 17 shows one example of a T cell response to hMPV.

**[0038]** FIG. 18 shows one example of a T cell response to hMPV including an antigen hierarchy.

**[0039]** FIG. 19 provides an exemplary of a T cell score that corresponds to hMPV ranking.

**[0040]** FIG. 20 illustrates a PIV3 molecule and its gene products, including N-P-M-F-HN-L.

**[0041]** FIG. 21 provides one example of a T cell response to PIV3.

**[0042]** FIG. 22 shows one example of a T cell response to PIV3 including an antigen hierarchy.

**[0043]** FIG. 23 provides an exemplary of a T cell score that corresponds to PIV3 ranking.

**[0044]** FIG. 24 demonstrates an example where Granzyme B is used to determine a percentage of responders vs. non-responders for the characterization of an immune response against a pathogen.

**[0045]** FIG. 25 demonstrates the frequency of PIV3-specific T cells targeting antigens M and N exhibiting a particular enrichment between Day 155 and Day 162.

**[0046]** FIG. 26 shows an example of clinical relevance of PIV3 T cells to control viral infection, where an increase in the frequency of PIV3-specific T cells had an inverse correlation with the symptoms of infection and viral detection in a representative patient with active infection post bone marrow transplant (BMT).

**[0047]** FIG. 27 illustrates the clinical relevance of the immune T cell response against different hMPV antigens.

**[0048]** FIG. 28 illustrate a therapeutic application of ranking where the top targets of a Virus X are identified as a source of antigen.

**[0049]** FIG. 29 illustrate a therapeutic application of ranking where the top targets of a Bacteria Y are identified as a source of antigen.

**[0050]** FIG. 30 illustrate a therapeutic application of ranking where the top targets of a Tumor Z are identified as a source of antigen.

**[0051]** FIG. 31 demonstrates phenotypic characteristics of a T cell product.

**[0052]** FIG. 32 shows the antigen specificity of CD4+ and CD8+ as detected by intracellular cytokine staining for antigens M and HN.

**[0053]** FIG. 33 illustrates one example of hMPV T cell manufacture.

**[0054]** FIG. 34 demonstrates expansion of T cells from an example as shown in FIG. 33.

**[0055]** FIG. 35 shows the phenotype of hMPV STs.

**[0056]** FIG. 36 provides results of a culture with HMVP-specific T cells resulted in a progressive decline in the HMPV target cells.

**[0057]** FIG. 37 shows that the cells in FIG. 35 were antigen-specific as detected by intracellular cytokine staining for relevant antigens.

**[0058]** FIG. 38 shows one example of a mathematical relationship for a definition for a product of T cells.

**[0059]** FIG. 39 demonstrates specificity and cytolytic capability of the cultures was assessed on Day 0, 10 and 20 for adenovirus-specific T cells.

**[0060]** FIG. 40 demonstrates specificity and cytolytic capability of the cultures was assessed on Day 0, 10 and 20 for BK virus specific T cells.

**[0061]** FIG. 41 demonstrates specificity and cytolytic capability of the cultures was assessed on Day 0, 10 and 20 for CMV specific T cells.

**[0062]** FIG. 42 illustrates administration to a patient of antigen-specific T cells generated from peripheral blood or leukapheresis product.

**[0063]** FIG. 43 illustrates off-the-shelf use of specific T cells.

**[0064]** FIG. 44 provides mathematical examples of when a product of T cells is or is not given to a patient.

**[0065]** FIG. 45 shows clinical outcome of a patient with active CMV infection treated with a CMV-specific T cell product defined by the mathematical example in FIG. 44.

**[0066]** FIG. 46 shows clinical outcome of a patient with active EBV infection treated with a EBV-specific T cell product defined by the mathematical example in FIG. 44.

**[0067]** FIG. 47 shows clinical outcome of a patient with active BKV infection treated with a BKV-specific T cell product defined by the mathematical example in FIG. 44.

## DETAILED DESCRIPTION

**[0068]** As used herein, the use of the word “a” or “an” when used in conjunction with the term “comprising” in the claims and/or the specification may mean “one,” but it is also consistent with the meaning of “one or more,” “at least one,” and “one or more than one.” Some embodiments of the invention may consist of or consist essentially of one or more elements, method steps, and/or methods of the invention. It is contemplated that any method or composition described herein can be implemented with respect to any other method or composition described herein.

**[0069]** As used herein, the term “biological activity” is defined as a biological change in the production of effector molecules, such as IFN gamma, granzyme B, IL2, TNF alpha, specific lysis of target cells, or expression of cell surface molecules such as CD25, CD69, CD27, CD28, or CD107 a/b, for example.

**I. [0070] General Embodiments**

**[0071]** In some embodiments of the disclosure, an individual is in need of the methods and/or compositions of the disclosure. In specific embodiments, the individual is immunocompromised (which for example, may be defined as an individual whose ability to fight infectious disease with the immune system is compromised or entirely absent for any reason). In specific embodiments, the immunocompromised individual has had a stem cell transplant, has had an organ transplant, and so forth. In another specific embodiment, the individual has cancer or is at risk of developing cancer.

**[0072]** Embodiments of the disclosure concern the establishment of a hierarchy of immunodominance for a pathogen or cancer, and in representative cases the pathogen is PIV (including at least PIV3), hMPV, cytomegalovirus, BK virus, human herpesvirus 6, adenovirus, Epstein Barr virus, BK virus, RSV, Influenza, Parainfluenza, Bocavirus, Coronavirus, LCMV, Mumps, Measles, Metapneumovirus, Parvovirus B, Rotavirus, West Nile Virus, JC, or HHV7. Cancer antigens may be from cancer of the lung, breast, brain, colon, skin, prostate, pancreas, endometrium, kidney, ovary, testes, bone, spleen, liver, gall bladder, thyroid, esophagus, intestine, bladder, rectum, anus, stomach, head and neck, throat, pituitary gland, or multiple myeloma or lymphoma, for example. In specific embodiments, when the pathogen is a virus, examples of thresholds of activity for distinguishing responders and non-responder is a value above 20 IFN gamma spot-forming cells (SFC)/ $2 \times 10^5$  input cells or 10 granzyme B SFC/ $2 \times 10^5$

input cells in ELIspot assays. One skilled in the art recognizes that these represent examples of biological activity used to define thresholds of activity. However, the examples of numerical thresholds to define biological activity are subject to change depending on the assays/tools used to measure biological activity.

**[0073]** In particular embodiments, one or more quantitative biological responses are utilized in a determination for rank of immunogenicity of antigens from a pathogen. In specific embodiments, the response is utilized to identify a critical level of T cell activity, including a level that can be used to determine responders vs. non-responders. In certain embodiments, a quantitative biological response is the production (such as secreted from the cell) or expression (such as membrane-bound on the cell) of a compound from T cells upon recognition of a particular target. In specific embodiments, the compound is IL1 $\alpha$ , IL1 $\beta$ , IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12 (p35+p40), IL-13, IL-14, IL-15, IL-16, IL-17a, IL-17B, IL-17F, IL-18, IL-19, IL-20, IL-21, IL-22, IL-23 (p90+p43), IL-25, IL-26, IL-27 (p28 +EBI3), IL-28A/B/IL29A, IL-30 (p28 subunit of IL-27), IL-31, IL-32, IL-33, IL-35 (p35 + EBI3), TNF $\alpha$ , LT $\alpha$ , LT $\beta$ , LIGHT, OX40L, CD25, CD45, CD40L, FASL, CD27L, CD30L, 4-1BBL, TRAIL, RANK Ligand, GM-CSF, IFN $\gamma$ , LIF, MIF, TGF $\beta$ 1, TGF $\beta$ 2, and/or TGF $\beta$ 3. In specific embodiments, the compound is IL2, IFN $\gamma$ , granzyme B, CD25, perforin, GM-CSF, and/or TNF $\alpha$ . In some embodiments, the biological response is the upregulation of one or more markers upon stimulation with a cognate antigen, such as CD25, CD27, CD28, CD45, CD69, and/or CD107.

**[0074]** The skilled artisan recognizes that the term SFC is utilized in reference to Enzyme-linked immunosorbent spot (ELIspot) technique that identifies cells that express or secrete a particular compound of interest. The technique employs the use of target protein-specific antibodies immobilized on suitable membranes. Compounds produced by cells of interest plated at varying densities are captured by a first antibody that recognizes the compound and then visualized by a second labeled antibody also specific for the compound. The enumeration of this reaction is a biomarker for certain methods disclosed herein.

## **II. [0075] Identification of Immunogenic Antigens and Efficacy Order Thereof**

**[0076]** Particular embodiments of the disclosure provide methods and compositions related to the identification of immunogenic antigen(s) that are particularly suitable for generation of and/or utilization in one or more types of immunotherapies. In specific embodiments, in a collection of antigens one or more antigens from the collection are identified

as being more immunogenic than other antigen(s). The collection of antigens may be multiple antigens from the same entity, such as from the same pathogen or from the same cancer type (including tumor antigens). In some cases, the collection of antigens include some or a majority of possible antigens from a pathogen or a cancer, and in certain cases the collection of antigens comprise all possible antigens from a pathogen or a cancer. The pathogen may be a virus, bacteria, or fungus, for example.

**[0077]** In general embodiments, a range of immunogenicity for a variety of antigens from a pathogen or cancer is ordered after at least a first and second challenge with the antigens to T cells, followed by determination of a mathematical value that reflects the effectiveness of response of the T cells, wherein the determination occurs after the second or a subsequent challenge. As an example, T cells from individuals are stimulated *in vitro* with a collection of antigens, and this initial stimulation can occur either with the different antigens being pooled for exposure to the T cells or with the different antigens being separated for exposure to the T cells. The stimulation may or may not occur in the presence of Th1-polarizing cytokines, in certain cases. Following a suitable amount of time (for example, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 days), the T cells are subjected to a second challenge, but in the second challenge the T cells are exposed to the different antigens in a separated manner (not pooled). Following a suitable amount of time (for example, 15 mins-72 hours), one or more biological responses of the T cells are evaluated, such as in a quantitative fashion. For example, as a biological response one can assess the production of one or more certain compound(s) (including produced and secreted from the cell or produced for cell surface expression, for example) as a measure of the activity of the T cells. The measurements may occur following a certain period of time after exposing the T cells to the second or subsequent challenge (for example, 15 mins-72 hours).

**[0078]** A quantitative output of the method for a particular antigen may be characterized as a function of one, two, or more values. In specific embodiments the quantitative output includes 1) the number of donors whose T cell progenies effectively recognized the particular antigen, and 2) the magnitude of the T cell response (for example, the number of SFC per certain number of input T cells).

**[0079]** In specific embodiments, a threshold by which the qualitative determination of whether or not the T cells are responding to the antigen is set. The parameters for defining a threshold of activity are defined as above and include determination of a level of unspecific

responses by measuring the magnitude of biological activity against an irrelevant target (antigens not expressed by the pathogen or tumor of interest) or against an unmanipulated PBMCs. This level of unspecific response then establishes a baseline to discriminate between responders and non-responders. Thus, in certain embodiments, a quantitated output of a biological response is measured against a threshold quantity to determine the efficacy and magnitude of the response from each plurality of T cells that is specific for one antigen. In at least some cases, the efficacy encompasses the percentage of individuals in a population that have a biological response that exceeds the threshold quantity. T cells that have greater magnitudes of response than the threshold are considered responders, whereas those with response values less than the threshold value are considered non-responders.

**[0080]** In specific embodiments, a threshold by which the qualitative determination of the magnitude of T cell to the antigen is established. An unspecific response may be determined based upon biological activity against an irrelevant target (antigens not expressed by the pathogen or tumor of interest) or against unmanipulated PBMCs is measure. This establishes a threshold for distinguishing responders from non-responders. A responder is signified when the response rises above the established unspecific response. A non-responder is signified with the response does not rise above the established unspecific response. Thus, in certain embodiments, a quantitated output of a biological response is measured against a threshold quantity to determine the efficacy and magnitude of the response from each plurality of T cells that is specific for one antigen. In at least some cases, the efficacy encompasses the percentage of individuals in a population that have a biological response that exceeds the threshold quantity. T cells that have greater magnitudes of response than the threshold are considered responders, whereas those with response values less than the threshold value are considered non-responders.

**[0081]** Quantitation of a T cell response may be measured by any suitable gauge, such as one or more changes identified intracellularly, secreted, or on the cell surface of cells in the culture. Production of certain compounds, either that are soluble or non-soluble, secreted or not secreted, may be measured. Such compounds may be of any kind, but in specific embodiments they are cytokines. Examples of specific compounds to measure includes IL1 $\alpha$ , IL1 $\beta$ , IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12 (p35+p40), IL-13, IL-14, IL-15, IL-16, IL-17a, IL-17B, IL-17F, IL-18, IL-19, IL-20, IL-21, IL-22, IL-23 (p90+p43), IL-25, IL-26, IL-27 (p28 +EBI3), IL-28A/B/IL29A, IL-30 (p28 subunit of IL-27), IL-31, IL-32, IL-33, IL-35 (p35 + EBI3), TNF $\alpha$ , LT $\alpha$ , LT $\beta$ , LIGHT, OX40L, CD40L, FASL, CD27L, CD30L, 4-1BBL, TRAIL, RANK Ligand,



GM-CSF, IFN $\gamma$ , LIF, MIF, TGF $\beta$ 1, TGF $\beta$ 2, TGF $\beta$ 3, and a combination thereof. In cases wherein one evaluates cell surface phenotypical changes, one can measure expression levels of CD11a, CD11c, CD16, CD25, CD27, CD28, CD31, CD38, CD40L, CD43, CD44, CD45, CD49d, CD62L, CD69, CD95, CD122, CD127, CXCR3, CCR5, CCR6, CCR7 and/or KLRG-1, for example. In some cases intracellular and extracellular changes are assessed, and such changes may comprise production/expression of IL-1 $\beta$ , IL2, IL4, IL6, IL12, IFN $\gamma$ , TNF $\alpha$ , TGF $\beta$ , CD107 and/or GM-CSF, for example.

**[0082]** In particular embodiments, the percentages of responders and the percentage of non-responders are utilized in a mathematical relationship with the magnitude of the biological activity that was in response to exposure to a desired agent that is intended to elicit a biological response, which in specific embodiments may represent the measurement of IFN gamma SFC. In particular cases, the mathematical relationship includes the product of the percentage of responders and the magnitude of the response as a ratio to the percentage of non-responders. In specific cases, the mathematical relationship is the product of the percentage of responders plus 1 times the magnitude of the response divided by the percentage of non-responders plus 1.

**[0083]** In particular embodiments, the percentages of responders and the percentage of non-responders are utilized in a mathematical relationship with the magnitude of the biological response (which in specific embodiments may represent the measurement of IFN gamma. In particular cases, the mathematical relationship includes the product of the percentage of responders and the magnitude of the response as a ratio to the percentage of non-responders. In specific cases, the mathematical relationship is the product of (percentage of responders +1) and the magnitude of the response divided by the percentage of non-responders +1.

**[0084]** In particular embodiments a mathematical relationship of a percentage of responders and magnitude of responses for a particular biological measurement is represented in a mathematical formula. Although more than one formula may be applicable, in specific embodiments the formula is as follows:

$$\text{[0085] } \frac{(\text{percentage of responders} + 1) \times \text{magnitude of biological response}}{(\text{percentage of non-responders} + 1)}$$

**[0086]** Once a value from this mathematical relationship is determined for each antigen, the values for each antigen can be compared and ordered in a hierarchy, for example of most

effective antigens to least effective antigens. This spectrum of immunogenicity provides information to a user that is in need of selecting the most suitable antigen(s), for example to be used in immunotherapy. In specific embodiments, following use of this method, one may select 1, 2, 3, or more of the most effective antigens from a collection of possible antigens to be used as the antigen(s) for immunotherapy. In specific embodiments, one selects only the most immunogenic antigen according to the output of the method, whereas in other cases one may select the 2, 3, 4 or more most immunogenic antigens according to the output of the method. In specific cases, one may select the most immunogenic antigen according to output of the method in addition to selecting the second-most immunogenic antigen according to output of the method, third-most immunogenic antigen according to output of the method, and/or fourth-most immunogenic antigen according to output of the method, and so forth. The immunotherapy that employs the most effective antigen(s) as identified in the methods of the disclosure may be of any kind, including a vaccine, immunogenic composition, adoptive T cell transfer, and so forth.

**[0087]** In certain embodiments, an individual that has a medical condition associated with a pathogen or that is seropositive for a pathogen, or that has cancer or is at risk for cancer, may be provided a therapeutically effective amount of immunotherapy that has been designed based on methods of characterizing immunogenic antigens as described herein.

**[0088]** Specific examples of identification of immunogenic antigens for exemplary pathogens and ordering of their immunogenicity/efficacy are provided in the Examples section below.

### **III. [0089] Mathematical and Other Correlations between Immune Cells and their Clinical Efficacy**

**[0090]** In particular embodiments of the disclosure, there are methods and compositions that are utilized to determine the efficacy of certain immune cells, such as T cells, NK cells, or NK T cells. The cells may or may not be engineered based on determination of a hierarchy of antigen immunodominance, as described above. In particular embodiments, biological features of a cell product is correlated to efficacy, including clinical efficacy.

**[0091]** In particular embodiments, T cells are produced upon an initial and/or second or subsequent stimulation with an antigen, such as a pathogenic or cancer (including tumor) antigen(s). The specificity and cytotoxicity of the T cells may be measured to provide insight to the clinical efficacy for a certain plurality of antigen-specific T cells. In doing so, one or more

biological measurements are assessed for the T cells, such as the amount of secreted compound from the cell and/or amount of cell surface markers on the cell. One or more biological measurements may be intracellular or on the cell surface. The measurements may occur following a certain period of time after exposing the T cells to one or more stimulations, such as within about 15 minutes but no later than 72 hours following one or more stimulations.

**[0092]** In particular embodiments, a value for the biological measurement of such T cells may be compared to a value for an unrelated entity, such as an unrelated or irrelevant target (for example, an antigen that is not present in a particular pathogen or cancer of interest). In at least certain examples the unrelated entity is unmanipulated cells, including unmanipulated PBMCs. In at least certain cases, a percentage of responders for a given antigen is determined using a ratio of a value for a biological measurement for the T cells in question and a value of an unmanipulated cellular counterpart. In specific cases, a percentage of responders for a given antigen is determined by dividing a value of a biological measurement for the cells with a value of a biological measurement of an unmanipulated cellular counterpart. In at least some embodiments, upon such calculation when the result is greater than or equal to 1, the individual whose T cells were tested in the method is considered a responder; when the calculation result is less than one, then the individual whose T cells were tested in the method is considered a non-responder.

**[0093]** In the context of specificity for the T cells, one can test the ability of the cells to produce a certain compound following exposure of the cells to the antigen, for example with at least two separate exposures to the antigen. In particular embodiments, the cells are considered specific when the sum of compound-producing spot-forming cells (SFC) directed against all antigens for a specific pathogen or cancer is  $\geq$  a certain value of SFCs/ $2 \times 10^5$  input cells dependent upon the production of which compound for the cells is being measured. For example, for IFN $\gamma$  production, the baseline to measure a response is  $\geq 20$  SFC/ $2 \times 10^5$  input cells, although for Granzyme B the baseline to measure a response is  $\geq 10$  SFC/ $2 \times 10^5$  input cells.

**[0094]** In the context of measuring cytotoxicity for the cells, the cytotoxicity may be determined by standard killing assays including co-culture assays, non-radioactive and radioactive labeling of antigen-loaded/expressing targets. One specific embodiment includes a chromium release assay where T cells are utilized as effectors and the targets are chromium-labeled autologous PHA blasts pulsed with the antigen(s) in question. Effector to target ratios

may be (or may be at least or no more than): 5:1, 10:1, 15:1, 20:1, 25:1, 30:1, 35:1, 40:1, 45:1, 50:1, 55:1, 60:1, 65:1, 70:1, 75:1, 80:1, 85:1, 90:1, or 95:1, *etc.* The cells may be considered to be cytotoxic against a particular pathogen or tumor antigen if the percentage of specific lysis of PHA blasts pulsed with the relevant antigens is higher than the lysis mediated by an irrelevant T cell product or unmanipulated PBMCs. In some conditions a threshold of activity in this assay can be considered as 10% specific lysis at a 40:1 effector to target ratio (for example, after subtracting the percentage of unspecific killing of target cells expressing an unrelated peptide (*e.g.*, not present in the pathogen or tumor of interest)).

**[0095]** Clinical efficacy for a particular plurality of antigen-specific T cells may be determined mathematically as a function of antigen specificity and/or cytotoxicity. In specific embodiments, a quantitative value for the efficacy of the cells is obtained through a mathematical relationship that utilizes values for biological measurements for the antigen-specific T cells and unmanipulated control cells, such as unmanipulated PBMCs and utilizes a value for specific killing.

**[0096]** One example of a specific mathematical formula that considers antigen specificity and cytotoxicity includes the following:

$$\text{[0097]} \quad ({}_R\text{TB}) + ({}_R\text{TK}) \geq 1$$

- **[0098]** where  ${}_R\text{TB}$  is defined as  $[(\text{Tbio-P}) + 1] / [(\text{Tbio-U}) + 1]$ , which when  $\geq 1$  will be equivalent to an  ${}_R\text{TB}$  value of 1 and when  $< 1$  will correspond to an  ${}_R\text{TB}$  value of 0; and
- **[0099]**  ${}_R\text{TK}$  is defined as  $[\text{TSpec-P}/\text{TCSpec}]$ , which when  $\geq 1$  will be equivalent to an  ${}_R\text{TK}$  value of 1 and when  $< 1$  will correspond to an  ${}_R\text{TK}$  value of 0 (see FIG. 38).

**[0100]** Tbio-P is defined as the biological characteristic(s) of the *in vitro* T cell product and Tbio-U are the biological characteristic(s) of unmanipulated PBMCs or irrelevant antigen. TSpec-P, or the specific killing ability of the *in vitro* T cell product, is defined as the percentage of lysed HLA-matched target cells expressing the cognate antigen at a predefined effector to target ratio, (*e.g.*, 40:1 effector to target ratio) after subtracting the percentage of unspecific killing by unmanipulated PBMCs of target cells expressing an irrelevant peptide, *i.e.*, an antigen or marker not present within the pathogen or tumor of interest at a predefined effector to target ratio (TCSpec).

**[0101]** In specific embodiments, when for the above-referenced formula the calculation of  $({}_R\text{TB}) + ({}_R\text{TK})$  is greater than or equal to 1, then the population of T cells being tested will be clinically efficacious. Such cells may be administered in therapeutically effective amounts to an individual in need thereof. When for the above-referenced formula the calculation of  $({}_R\text{TB}) + ({}_R\text{TK})$  is less than one, the population of T cells being tested will not be clinically efficacious. Such cells may not be administered in therapeutically effective amounts to an individual in need thereof.

**[0102]** Specific examples of mathematical correlations between engineered immune cells and their clinical efficacy are provided in the Examples section below.

**[0103]** Finally, if multiple products are available for clinical use as defined by the formula  $({}_R\text{TB}) + ({}_R\text{TK}) \geq 1$  then products can be ranked either using the raw numerical data  $({}_R\text{TB})$  and/or  $({}_R\text{TK})$  prior to transformation to a binary output. Alternatively the supplemental formula  $\alpha({}_R\text{TB}) + \beta({}_R\text{TK}) = \phi$  can be applied. In this supplemental formula  $\phi$  is defined as a clinical efficacy variable (the higher the value, the ‘better’ the product).

- **[0104]**  $\alpha({}_R\text{TB}) + \beta({}_R\text{TK}) = \phi$
- **[0105]** Where  ${}_R\text{TB}$  is defined as the value resulting from  $[(\text{Tbio-P}) + 1] / [(\text{Tbio-U}) + 1]$
- **[0106]** Where  ${}_R\text{TK}$  is defined as the value resulting from  $[(\% \text{TSpec-P}) / \text{TCSpec}]$
- **[0107]** where  $\alpha$  and  $\beta$  are defined as weighting coefficients dependent upon variables including but not limited to therapeutic applications, manufacturing processes, peptide mixtures, cell lines, *etc.*

**[0108]** where  $\phi$  is defined as a clinical efficacy value that may be used to determine a ranking of clinical efficacy among therapeutic products

#### **IV. [0109] Methods of Generating Antigen-Specific T cells**

**[0110]** In specific embodiments, the present disclosure concerns the development of antigen-specific T cells that target at least one antigen from a pathogen (including viral, bacterial, or fungal) or other disease-associated antigen, including tumor antigens. In certain aspects of the disclosure, the present disclosure concerns the development of antigen-specific T cells that target antigens from at least one virus, for example.

**[0111]** In one embodiment, a healthy donor provides a sample, such as a blood sample or leukapheresis product of leukopak. PBMCs are obtained and exposed to the entire pathogen or one or more parts of the pathogen. The cells may also be exposed to one or more cytokines. Following at least 48 hours in culture the cells are fractioned into multiple tubes and re-challenged with individual antigens. The cells may also be exposed to one or more cytokines.

**[0112]** Embodiments of the disclosure concern the generation of antigen-specific T cell lines with specificity against one or more pathogenic or cancer antigens. In certain embodiments, the generation of antigen-specific T cells with such specificity does not utilize dendritic cells in the preparation of such lines, although in alternative embodiments dendritic cells are utilized in standard methods. In some cases, the antigen is presented to PBMCs in the form of one or more peptides that span some or all of the antigen. The antigenic peptides may be provided to the PBMCs in a library of peptide mixtures, which may be referred to as pepmixes. In other aspects of the disclosure, in the preparation of the antigen-specific T cells the disclosure allows for the pooling of a variety of pepmixes.

**[0113]** In some embodiments of the disclosure, following antigen selection methods as encompassed herein, there is a method of generating antigen-specific T cells that target at least one, two, or more antigens from one, two, or more viruses, comprising the steps of : contacting a plurality of peripheral blood mononuclear cells with at least two libraries of peptides, the libraries of peptides each comprising peptides that correspond to a particular viral antigen; and expanding the plurality of cells in the presence of one or more cytokines. In specific embodiments, the method occurs in the absence of exposing the libraries to isolated peptide-pulsed dendritic cells prior to expanding the antigen-specific T cells. In certain embodiments, the one or more cytokines are selected from the group consisting of IL4, IL7, IL12, IL21, IL15, IL6 and a combination thereof. In some embodiments, the peptides are further defined as peptides that overlap in sequence to span part or all of a viral antigen. For example, in certain aspects the peptides overlap by at least three, four, five, or six amino acids, and in some embodiments the peptides are at least six, seven, or eight or more amino acids in length.

**[0114]** In at least some methods of the disclosure, the antigen-specific T cells generated thereby are administered to an individual, for example, an immunocompromised individual. In some cases, the individual has had allogeneic stem cell transplant. In specific embodiments, the cells are administered by injection, such as intravenous, intramuscular, intradermal,

subcutaneous, intraperitoneal injection, and so forth, for example. In some embodiments, the individual has lymphoma or leukemia. In some embodiments, the antigen-specific T cells are further defined as polyclonal CD4+ and CD8+ antigen-specific T cells. The PBMCs may be allogeneic to the individual or may be autologous to the individual.

**[0115]** The infection in the individual (or risk or susceptibility thereof) may be from any kind of pathogen, but in specific embodiments the infection is the result of one or more viruses. The pathogenic virus may be of any kind, but in specific embodiments it is from one of the following families: *Adenoviridae*, *Picornaviridae*, *Herpesviridae*, *Hepadnaviridae*, *Flaviviridae*, *Retroviridae*, *Orthomyxoviridae*, *Paramyxoviridae*, *Papovaviridae*, *Polyomavirus*, *Rhabdoviridae*, *Arenaviridae*, *calciviridae*, *coronaviridae*, *parvoviridae*, *reoviridae*, *poxviridae*, or *Togaviridae*. In some embodiments, the virus produces antigens that are immunodominant or subdominant or produces both kinds. In specific cases, the virus is selected from the group consisting of EBV, CMV, Adenovirus, BK virus, HHV6, RSV, Influenza, Parainfluenza, Bocavirus, Coronavirus, LCMV, Mumps, Measles, Metapneumovirus, Parvovirus B, Rotavirus, West Nile Virus, Spanish influenza, and a combination thereof.

**[0116]** In some aspects the infection is the result of a pathogenic bacteria, and the present disclosure is applicable to any type of pathogenic bacteria. Exemplary pathogenic bacteria include at least *Bacillus anthracis*, *Bacillus cereus*, *Bartonella henselae*, *Bartonella Quintana*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Borrelia garinii*, *Borrelia afzelii*, *Borrelia recurrentis*, *Brucella abortus*, *Brucella canis*, *Brucella melitensis*, *Brucella suis*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Chlamydophila psittaci*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Clostridium tetani*, *Corynebacterium diphtheria*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Francisella tularensis*, *Haemophilus influenza*, *Helicobacter pylori*, *Legionella pneumophila*, *Leptospira interrogans*, *Leptospira santarosai*, *Leptospira weilii*, *Leptospira noguchii*, *Listeria monocytogenes*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycobacterium ulcerans*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitides*, *Pseudomonas aeruginosa*, *Rickettsia rickettsii*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus saprophyticus*, *Streptococcus agalactiae*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Yersinia pestis*, *Yersinia enterocolitica*, or *Yersinia pseudotuberculosis*, for example.

[0117] In some aspects the infection is the result of a pathogenic fungus, and the present disclosure is applicable to any type of pathogenic fungus. Exemplary pathogenic fungi include at least *Candida*, *Aspergillus*, *Cryptococcus*, *Histoplasma*, *Pneumocystis*, *Stachybotrys*, *Blastomyces*, *Coccidioides*, *Cladosporium*, *Exserohilum*, *Penicillium marneffei*, *mucormycetes*, *Sporothrix*, or *Tinea*.

[0118] In some embodiments of the disclosure, the individual may be at risk or have cancer and the present disclosure is applicable to any type of cancer. The cancer may be of any kind or origin, but in specific embodiments it is of the following types: carcinoma, sarcoma, leukemia, lymphoma, multiple myeloma, melanoma, brain and spinal cord tumors, germ cell tumors, blastomas, neuroendocrine tumors, carcinoid tumors and benign tumors. In specific cases, the cancer is selected from the group consisting of Acute Lymphoblastic Leukemia (ALL), acute Myeloid Leukemia (AML), Adrenocortical Carcinoma, Adrenal Cortex Cancer, AIDS-Related Cancers, Kaposi Sarcoma, AIDS-Related Lymphoma, Primary CNS Lymphoma, Anal Cancer, Appendix Cancer, Astrocytomas, Atypical Teratoid/Rhabdoid Tumor, Basal Cell Carcinoma, Bile Duct Cancer, Bladder Cancer, Bone Cancer (including Ewing Sarcoma and Osteosarcoma and Malignant Fibrous Histiocytoma), Breast Cancer, Bronchial Tumors, Burkitt Lymphoma, Gastrointestinal Carcinoid Tumor, Carcinoid Tumors, Cardiac (Heart) Tumors, Embryonal Tumors, Germ Cell Tumors, Lymphoma, Cervical Cancer, Cholangiocarcinoma, Chordoma, Chronic Lymphocytic Leukemia (CLL), Chronic Myelogenous Leukemia (CML), Chronic Myeloproliferative Neoplasms, Colorectal Cancer, Craniopharyngioma, Cutaneous T-Cell Lymphoma, Ductal Carcinoma In Situ (DCIS), Embryonal Tumors, Endometrial Cancer, Ependymoma, Esophageal, Esthesioneuroblastoma, Extracranial Germ Cell Tumor, Extragonadal Germ Cell Tumor, Fallopian Tube Cancer, Fibrous Histiocytoma of Bone, Malignant, and Osteosarcoma, Gallbladder Cancer, Gastric (Stomach) Cancer, Gastrointestinal Carcinoid Tumor, Gastrointestinal Stromal Tumors (GIST), Extracranial Germ Cell Tumor, Extragonadal Germ Cell Tumor, Ovarian Cancer, Testicular Cancer, Gestational Trophoblastic Disease Gliomas, Hairy Cell Leukemia, Head and Neck Cancers, Heart Tumors, Hepatocellular Cancer, Langerhans Cell Histiocytosis, Hodgkin Lymphoma, Hypopharyngeal Cancer, Intraocular Melanoma, Islet Cell Tumors, Pancreatic Neuroendocrine Tumors, Pancreatic Cancer, Kaposi Sarcoma, Laryngeal Cancer, Laryngeal Papillomatosis, Leukemia, Lip and Oral Cavity Cancer, Liver Cancer, Lung Cancer, Non-Hodgkin Lymphoma, Malignant Fibrous Histiocytoma of Bone, Osteosarcoma, Melanoma, Intraocular Melanoma, Merkel Cell



Carcinoma, Skin Cancer, Mesothelioma, Malignant Mesothelioma, Metastatic Squamous Neck Cancer with Occult Primary, Midline Tract Carcinoma Involving NUT Gene, Mouth Cancer - Head and Neck Cancer, Multiple Endocrine Neoplasia Syndromes, Multiple Myeloma/Plasma Cell Neoplasms, Mycosis Fungoides, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Chronic Myeloproliferative Neoplasms, Myelogenous Leukemia, Chronic (CML), Nasal Cavity and Paranasal Sinus Cancer, Nasopharyngeal Cancer, Neuroblastoma, Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Oral Cancer, Lip and Oral Cavity Cancer, Oropharyngeal Cancer, Oral Cavity Cancer, Osteosarcoma, Pancreatic Cancer, Papillomatosis, Paraganglioma, Paranasal Sinus and Nasal Cavity Cancer, Parathyroid Cancer, Penile Cancer, Pharyngeal Cancer, Pheochromocytoma, Pituitary Tumor, Plasma Cell Neoplasm/Multiple Myeloma, Pleuropulmonary Blastoma, Primary Central Nervous System (CNS) Lymphoma, Peritoneal Cancer, Prostate Cancer, Rectal Cancer, Colorectal Cancer, Renal Cell (Kidney) Cancer, Retinoblastoma, Rhabdomyosarcoma, Salivary Gland Cancer, Salivary Gland Tumors, Sarcoma, Osteosarcoma, Rhabdomyosarcoma, Uterine Sarcoma, Uterine Cancer, Vascular Tumors, Sézary Syndrome, Skin Cancer, Small Cell Lung Cancer, Small Intestine Cancer, Soft Tissue Sarcoma, Squamous Cell Carcinoma, Squamous Neck Cancer, Stomach (Gastric) Cancer, Cutaneous T-Cell Lymphoma, Testicular Cancer, Throat Cancer, Thymoma, Thymic Carcinoma, Thyroid Cancer, Thyroid Tumors, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer, Uterine Cancer, Endometrial, Uterine Sarcoma, Vaginal Cancer, Vascular Tumors, Vulvar Cancer, Waldenström Macroglobulinemia (Non-Hodgkin Lymphoma) and Wilms Tumor.

**[0119]** In some embodiments of the disclosure, a library of peptides is provided to PBMCs ultimately to generate antigen-specific T cells. The library in particular cases comprises a mixture of peptides (“pepmixes”) that span part or all of the same antigen. Pepmixes utilized in the disclosure may be from commercially available peptide libraries, for example made up of peptides that are 15 amino acids long and overlapping one another by 11 amino acids, in certain aspects. In some cases, they may be obtained commercially and/or be generated synthetically. Examples include those from JPT Technologies (Springfield, VA) or Miltenyi Biotec (Auburn, CA). In particular embodiments, the peptides are at least 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 35 or more amino acids in length, for example, and in specific embodiments there is overlap of at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, or 34

amino acids in length, for example. The mixture of different peptides may include any ratio of the different peptides, although in some embodiments each particular peptide is present at substantially the same numbers in the mixture as another particular peptide.

**[0120]** In specific embodiments, cells of any kind related to the disclosure may be cultured in suitable media alone or supplemented with cytokines and they may be cultured in a gas permeable culture device (such as G-Rex10 (Wilson Wolf Manufacturing Corporation, New Brighton, MN)), other culture apparatus, bioreactor or system or tissue culture plates. Media and/or cytokines may be replenished and cultures may be split following a suitable period of time. In specific embodiments, one or more particular cytokines are employed, including IL7, IL4, IL15, IL12, IL21 and /or IL2, for example.

**[0121]** Embodiments of preparing T cells may comprise the steps of contacting a plurality of peripheral blood mononuclear cells with one, two, or more libraries of peptides, wherein the library or libraries of peptides each comprise peptides that correspond to one or more particular antigens; and expanding the plurality of cells in the presence of one or more cytokines, optionally IL4, IL15, IL21, IL12, IL6 and/or IL7.

#### **V. [0122] Kits of the Disclosure**

**[0123]** Any of the compositions described herein may be comprised in a kit. In a non-limiting example, cells, cytokines, sample extraction apparatuses, cell culture media, cell culture flasks, peptides, proteins, viruses, and/or other reagents may be comprised in a kit.

**[0124]** The kits may comprise suitably aliquoted compositions utilized in the present disclosure. The components of the kits may be packaged either in aqueous media or in lyophilized form. The container means of the kits will generally include at least one vial, test tube, flask, bottle, syringe or other container means, into which a component may be placed, and preferably, suitably aliquoted. Where there are more than one component in the kit, the kit also will generally contain a second, third or other additional container into which the additional components may be separately placed. However, various combinations of components may be comprised in a vial. The kits of the present disclosure also will typically include a means for containing the compositions in close confinement for commercial sale. Such containers may include injection or blow-molded plastic containers into which the desired vials are retained. In specific embodiments, the kit comprises one or more means for obtaining blood cells and/or bone marrow cells.

**[0125]** When the components of the kit are provided in one and/or more liquid solutions, the liquid solution is an aqueous solution, with a sterile aqueous solution being particularly preferred. The compositions may also be formulated into a syringeable composition. In which case, the container means may itself be a syringe, pipette, and/or other such like apparatus, from which the formulation may be applied to an infected area of the body, injected into an animal, and/or even applied to and/or mixed with the other components of the kit. However, the components of the kit may be provided as dried powder(s). When reagents and/or components are provided as a dry powder, the powder can be reconstituted by the addition of a suitable solvent. It is envisioned that the solvent may also be provided in another container means.

## EXAMPLES

**[0126]** The examples provided herewith are included to demonstrate particular embodiments of the disclosure. It should be appreciated by those of skill in the art that the techniques disclosed in the examples that follow represent techniques discovered by the inventor to function well in the practice of the inventions, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the disclosure.

### EXAMPLE 1

#### IMMUNOGENIC ANTIGEN IDENTIFICATION AND CORRELATION TO CLINICAL EFFICACY

**[0127]** In particular embodiment, this disclosure concerns a process for identifying antigens derived from pathogens (viruses, bacteria or fungi) and/or cancer that are immunogenic and have important therapeutic applications. In certain aspects, the process involves compartmentalizing part or all of an entire organism, such as a virus, into fragments known as antigens and establishing a rank of significant therapeutic antigen targets. This information can then be used to select particularly useful fragment(s) or combination of fragments in an organism for the development of treatments, such as vaccines, adoptive cell therapy or any combination thereof. Importantly, this process comprises the identification of immunogenic antigens and

therefore is not restricted to a single HLA type unlike previous methods, which may function on the epitope/HLA-restricted level.

**[0128]** One example of this could include the following scenario wherein Virus X is compartmentalized into 6 fragments, or antigens, named A, B, C, D, E, and F (FIG. 1). These fragmented components of Virus X are then used to perform an *in vitro* stimulation of PBMCs or T cells isolated from healthy individuals (this stimulation can occur either with these fragments pooled together or individually). In this example, T cells obtained from 100 (for example, a minimum of 5 and with no maximum) healthy seropositive individuals for Virus X were cultured *in vitro* with individual or pooled fragmented targets for a period of 10 days (for example, in a range of 6–14 days) in the presence of Th1-polarizing cytokines. After this initial T cell challenge, the T cells were extracted and challenged again but this time only with individual fragments (antigens). After this second challenge, T cells were assessed for their response. One method to assess T cell response is to evaluate IFN $\gamma$  production, although other methods to evaluate T cell response are known and can be used. In this example, the IFN $\gamma$  production was assessed using IFN $\gamma$  ELISpot. This information can then be processed to determine a threshold of responders vs. non-responders as well as the magnitude of response. A threshold of activity (which may be referred to as a benchmark) for different pathogens (including viruses) and cancer may or may not be the same value for each biological activity measured. For example, different viruses may utilize the threshold for measuring IFN $\gamma$  production as 20 SFC/2x10<sup>5</sup>. As another example, different viruses may utilize the threshold for measuring Granzyme B as 10 SFC/2x10<sup>5</sup>.

**[0129]** Using this technique, the threshold of responders was determined to be a value above 30 SFC per 2x10<sup>5</sup> input T cells. A threshold of response for biological activity may be (or may be at least or no more than) 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 525, 550, 575, 600, 625, 650, 675, 700, 725, 750, 775, 800, 825, 850, 875, 900, 925, 950, 975, 1000, 1250, 1500, 1750, 2000, 2250, 2500, 3000, 3500, 4000, 4500, or more SFC/2x10<sup>5</sup>.

**[0130]** An example of these results as illustrated in FIG. 1 follows:

**[0131]** Antigen A was recognized by 80% of donors (n=80) with a mean of 500 SFC/2x10<sup>5</sup> input T cells.

**[0132]** Antigen B was recognized by 70% of donors (n=70) with a mean of 200 SFC/2x10<sup>5</sup> input T cells.

**[0133]** Antigen C was recognized by 30% of donors (n=30) with a mean of 100 SFC/2x10<sup>5</sup> input T cells.

**[0134]** Antigen D was recognized by 90% of donors (n=90) with a mean of 450 SFC/2x10<sup>5</sup> input T cells.

**[0135]** Antigen E was recognized by 80% of donors (n=80) with a mean of 1000 SFC/2x10<sup>5</sup> input T cells.

**[0136]** Antigen F was recognized by 30% of donors (n=30) with a mean of 50 SFC/2x10<sup>5</sup> input T cells.

**[0137]** To next define a hierarchy of immunodominance, the inventors developed a TC (T Cell)-test that takes into consideration both the frequency of responding donors and the number of reactive T cells. The formula is as follows:

$$\text{[0138]} \quad \frac{(\% \text{ of responders} + 1)}{(\% \text{ of non-responders} + 1)} \times \text{Magnitude of response (SFC/2x10}^5\text{)}$$

$$\text{[0139]} \quad (\% \text{ of non-responders} + 1)$$

**[0140]** Thus, a TC-score can be applied to each of the target antigens, as shown in FIG. 2. Using this formula, for example, Antigen A is applied a score of 1928.5, Antigen B is applied a score of 458.1, Antigen C is applied a score of 43.6, Antigen D is applied a score of 3722.7, Antigen E is applied a score of 3857.1 and Antigen F is applied a score of 21.8. Thus, the antigens can be organized into the following hierarchy of immunodominance:

$$\text{[0141]} \quad E > D > A > B > C > F$$

**[0142]** Hence, in order to provide protective immunity to a patient infected with Virus X, the following represents the identification of desired target or combination of targets (FIGS. 3, 4, and 5):

- (a) **[0143]** the most immunodominant target antigen (Antigen E)
- (b) **[0144]** a combination of the two most immunodominant targets (E + D)
- (c) **[0145]** a combination of the three most immunodominant targets (E + D + A)
- (d) **[0146]** a combination of the four most immunodominant targets (E + D + A + B)
- (e) **[0147]** a combination of the five most immunodominant targets (E + D + A + B + C)
- (f) **[0148]** a combination of the six most immunodominant targets (E + D + A + B + C + F)

**[0149]** It is important to note the method described above can be applied to pathogens other than viruses, including but not limited to bacteria, parasites and fungi as well as tumors.

**[0150]** Therefore, a second example of the process described above could include the following scenario where Bacteria Y is compartmentalized into 8 fragments, or antigens, named A, B, C, D, E, F, G and H. Utilizing the process described above, an example of the results for Bacteria Y as illustrated in FIG 6 follows:

**[0151]** Antigen A was recognized by 90% of donors (n=90) with a mean of 20 SFC/2x10<sup>5</sup> input T cells.

**[0152]** Antigen B was recognized by 50% of donors (n=50) with a mean of 800 SFC/2x10<sup>5</sup> input T cells.

**[0153]** Antigen C was recognized by 70% of donors (n=70) with a mean of 1000 SFC/2x10<sup>5</sup> input T cells.

**[0154]** Antigen D was recognized by 30% of donors (n=30) with a mean of 300 SFC/2x10<sup>5</sup> input T cells.

**[0155]** Antigen E was recognized by 20% of donors (n=20) with a mean of 150 SFC/2x10<sup>5</sup> input T cells.

**[0156]** Antigen F was recognized by 60% of donors (n=60) with a mean of 600 SFC/2x10<sup>5</sup> input T cells.

**[0157]** Antigen G was recognized by 40% of donors (n=40) with a mean of 450 SFC/2x10<sup>5</sup> input T cells.

**[0158]** Antigen H was recognized by 80% of donors (n=80) with a mean of 50 SFC/2x10<sup>5</sup> input T cells.

**[0159]** The hierarchy of immunodominance was determined utilizing the TC-test and applying a TC-scores to each of the Bacteria Y target antigens, as illustrated in FIG 7. For instance, Antigen A is applied a score of 167.45, Antigen B is applied a score of 800, Antigen C is applied a score of 2290.32, Antigen D is applied a score of 130.99, Antigen E is applied a score of 38.89, Antigen F is applied a score of 892.68, Antigen G is applied a score of 302.46, and Antigen H is applied a score of 192.86. Thus, the antigens can be organized into the following hierarchy;

**[0160]** C > F > B > G > H > A > D > E

**[0161]** Thus, in order to provide protective immunity to a patient infected with Bacteria Y, the following represents the identification of desired target or combination of target antigens (FIGS. 8, 9 and 10):

**[0162]** (a) the most immunodominant target antigen (Antigen C)

**[0163]** (b) a combination of the two most immunodominant targets (C + F)

**[0164]** (c) a combination of the three most immunodominant targets (C + F + B)

**[0165]** (d) a combination of the four most immunodominant targets (C + F + B + G)

**[0166]** (e) a combination of the five most immunodominant targets (C + F + B + G + H)

**[0167]** (f) a combination of the six most immunodominant targets (C + F + B + G + H + A)

**[0168]** (g) a combination of the six most immunodominant targets (C + F + B + G + H + A)

**[0169]** (h) a combination of the seven most immunodominant antigens (C + F + B + G + H + A + D)

**[0170]** (i) a combination of the seven most immunodominant antigens (C + F + B + G + H + A + D + E)

**[0171]** A third example of identifying the hierarchy of immunodominant antigens could include the following scenario where Tumor Z is compartmentalized into 4 fragments, or antigens, named A, B, C, D, E (FIG. 11).

**[0172]** In this example, T cells obtained from 100 individuals with Tumor Z were *cultured in vitro* with individual or pooled fragmented targets for a period of 10 days in presence of Th1-polarizing cytokines. After this initial T cell challenge, the T cells were extracted and challenged again but this time only with antigens. After this second challenge, IFN $\gamma$  production was assessed using IFN $\gamma$  ELIspot.

**[0173]** The threshold of responders was determined to be a value above 20 SFC per  $2 \times 10^5$  input T cells. However, a threshold of response for biological activity may be (or may be at least or no more than) 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 125, 150, 175, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 525, 550, 575, 600, 625, 650, 675, 700, 725, 750, 775, 800, 825, 850, 875, 900, 925, 950, 975, 1000, 1250, 1500, 1750, 2000, 2250, 2500, 3000, 3500, 4000, 4500, or more SFC/ $2 \times 10^5$ .

**[0174]** An example of these results follows:

**[0175]** Antigen A was recognized by 95% of donors (n=95) with a mean of 225 SFC/ $2 \times 10^5$  input T cells.

**[0176]** Antigen B was recognized by 70% of donors (n=70) with a mean of 700 SFC/ $2 \times 10^5$  input T cells.

**[0177]** Antigen C was recognized by 10% of donors (n=10) with a mean of 50 SFC/ $2 \times 10^5$  input T cells.



**[0178]** Antigen D was recognized by 20% of donors (n=20) with a mean of 300 SFC/2x10<sup>5</sup> input T cells.

**[0179]** Antigen E was recognized by 75% of donors (n=75) with a mean of 655 SFC/2x10<sup>5</sup> input T cells.

**[0180]** The hierarchy of response was determined using the TC-test and applying a TC-score to each of the target antigens, as shown in Figure 11. For instance, Antigen A was assigned a score of 3600; Antigen B was assigned a score of 1603.23; Antigen C was applied a score of 6.04; Antigen D was assigned a score of 130.99; and Antigen E was assigned a score of 38.89. Therefore, the antigens can be organized in the following hierarchy (FIG. 12):

**[0181]**  $A > E > B > D > C$

**[0182]** Thus, in order to provide protective immunity to a patient with Tumor Z, the following represents the identification of desired target or combination of targets (FIGS. 13, 14 and 15):

**[0183]** (a) the most immunodominant target antigen (Antigen A)

**[0184]** (b) a combination of the two most immunodominant targets (A + E)

**[0185]** (c) a combination of the three most immunodominant targets (A + E + B)

**[0186]** (d) a combination of the four most immunodominant targets (A + E + B + D)

**[0187]** (e) a combination of the five most immunodominant targets (A + E + B + D + C)

## EXAMPLE 2

### IDENTIFYING THE HIERARCHY OF IMMUNODOMINANCE FOR HMPV

**[0188]** Human Metapneumovirus (HMPV) is an important causative agent of acute respiratory disease in infants, the elderly and immunocompromised individuals (Wen SC & Williams JV Clin. Vaccine Immunol. 2015).

**[0189]** **Virology**

**[0190]** HMPV is an enveloped, negative-sense, single-stranded RNA virus of the Metapneumovirus genus, Pneumovirinae subfamily, within the Paramyxoviridae family. The HMPV genome contains 8 genes, in the order 3'-N-P-M-F-M2-SH-G-L-5', encoding 9 proteins (FIG. 16).

**[0191]** There are three transmembrane glycoproteins on the virion surface: small hydrophobic (SH) protein, a heavily glycosylated putative attachment protein (G), and the fusion (F) glycoprotein, which mediates viral fusion and entry. While the function of the SH protein is unclear, several studies suggest a role for this protein in inhibiting the innate and adaptive immune responses. The matrix protein (M) lines the virion beneath the viral membrane and, analogously to the RSV M protein, plays a role in viral assembly and budding. The RNA genome is entirely encapsidated by the nucleoprotein (N) to form the nucleocapsid (sometimes called the ribonucleoprotein complex). The N protein, phosphoprotein (P), M2-1 protein, and large RNA-dependent RNA polymerase protein (L), associate with the RNA genome to form the viral RNA polymerase complex. The second M (M2) gene encodes two proteins: M2-1, which promotes transcription processivity in RSV and is essential for the synthesis of full-length mRNAs, and M2-2, which balances transcription and genome replication (Wen SC and Williams JV *Clin. Vaccine Immunol.* 2015).

#### **[0192] Transmission**

**[0193]** HMPV is thought to be transmitted by direct or close contact with contaminated secretions, which may involve saliva, droplets or large particle aerosol. HMPV RNA is found in excretions five days to two weeks after initiation of symptoms. However, the extent of contagiousness is unknown since detection of HMPV RNA in respiratory samples from patients recovering from infection does not per se indicate viable contagious viral particles (Haas LE et al. *Viruses* 2013).

#### **[0194] Epidemiology and Clinical Features**

**[0195]** HMPV is commonly found in the pediatric population, with high susceptibility rates in children less than 2 years old (Panda S et al. *Int. J. Infect. Dis.* 2014). In a retrospective study done on nasal-wash specimens obtained over a 25-year period from otherwise-healthy children presenting with acute respiratory illness, 20% of nasal-wash specimens contained HMPV RNA or viable virus (recovered in culture). The mean age of HMPV-infected children

was 11.6 months, and the majority of the illnesses occurred in late winter/early spring (Wen SC & Williams JV Clin. Vaccine Immunol. 2015).

**[0196]** The proportion of HMPV infections in adults varies between 3%–7.1%. This is higher (ranging from 4.3%–13.2%) in hospitalized adults (Haas LE et al. Viruses 2013). HMPV infection in adults normally shows only mild flu-like symptoms. However, in some adult cases (especially elderly adults), severe complications such as chronic obstructive pulmonary disease (COPD) can occur. Dyspnea is more likely in adults as compared to children. HMPV infection has also been reported in several immunocompromised patients, such as lung transplant recipients, patients with hematological malignancies, and hematopoietic stem cell transplant recipients (Panda S et al. Int. J. Infect. Dis. 2014). Clinical course in these patients is prolonged and respiratory failure may develop (Haas LE et al. Viruses 2013).

#### **[0197] Prevention and Treatment**

**[0198]** Although there are currently no HMPV vaccines licensed for use in humans, a variety of strategies including the use of inactivated virus, subunit protein, virus-like particles, live attenuated virus and chimeric virus have been investigated in animal models.

**[0199]** Several monoclonal antibodies have been developed to target the HMPV fusion protein. Two murine MAbs, MAb 234 and MAb 338, exhibited high-affinity binding to F protein and were effective when administered prophylactically or therapeutically in animal models. Similarly, human monoclonal antibodies, MPE8 and 54G10 exhibited prophylactic and therapeutic efficacy against HMPV in mouse models.

**[0200]** Treatment for HMPV infection in humans is mainly supportive. Ribavirin, a nucleoside analog was shown to have efficacy against HMPV both *in vitro* and in BALB/c mice. However, ribavirin is expensive, can cause adverse effects, such as hemolytic anemia, and is a potential teratogen. Furthermore, no controlled trials have been performed to study its efficacy in treating HMPV infection, though there are numerous anecdotal reports. Ribavirin has been administered to patients with severe HMPV infections, in some cases with intravenous immunoglobulin (IVIg). IVIg has antiviral activity against HMPV *in vitro*, although it requires infusions of large fluid volumes and is associated with adverse events in children with congenital heart disease (Wen SC & Williams JV Clin. Vaccine Immunol. 2015).

#### **[0201] Immune Response and Correlates of Protection**

**[0202]** Adaptive immune response (humoral and cellular immunity) is the most important aspect of protective immunity against HMPV. Indeed, animal studies show that passive transfer of antibody is sufficient to protect from HMPV replication. T cells are also important for viral clearance. Depletion of both CD4+ and CD8+ T cells resulted in higher viral titers after HMPV challenge in BALB/c mice (Wen SC & Williams JV Clin. Vaccine Immunol. 2015). In addition, human patients with previous HMPV respiratory disease were shown to have CD8+ T cell responses to HMPV proteins (Wen SC & Williams JV Clin. Vaccine Immunol. 2015). Therefore assessing the immunodominant hierarchy of HMPV is necessary to develop new therapeutic strategies.

**[0203] Establishing a hierarchy of immunodominance for hMPV**

**[0204]** Applying the process and TC-test described in Example 1, the following represents a novel characterization of T cell response for hMPV:

**[0205]** hMPV was compartmentalized into the following fragments: SH, M, L, G, F, M2-2, P, M2-1 and N. The percentage of responders were 3.4% for SH, 79.3% for M, 44.8% for L, 31% for G, 96.5% for F, 0% for M2-2, 68.9% for P, 79.3% for M2-1 and 86.2% for N and a magnitude of response of 34 for SH, 154 for M, 125 for L, 62 for G, 300 for F, 0 for M2-2, 130 for P, 167 for M2-1 and 220 for N. Applying the TC-test, we identified a TC-score of 1.53 for SH, 569.87 for M, 101.87 for L, 28.34 for G, 6500 for F, 0 for M2-2, 283.08 for P, 617.97 for M2-1, and 1178.38 for M (FIGS. 17-18). Applying the TC-score, the inventors ranked the different hMPV antigens (FIG. 19) as follows:

**[0206]**  $F > N > M2-1 > M > P > L > G > SH > M2-2$

**[0207]** Hence, in order to provide protective immunity to a patient infected with HMPV, the following represents the identification of desired target or combination of targets (FIG. 19):

- (a) **[0208]** the most immunodominant target antigen (Antigen F)
- (b) **[0209]** a combination of the two most immunodominant targets (F + N)
- (c) **[0210]** a combination of the three most immunodominant targets (F + N + M2-1)
- (d) **[0211]** a combination of the four most immunodominant targets (F + N + M2-1 + M)

- (e) **[0212]** a combination of the five most immunodominant targets (F + N + M2-1 + M + P)
- (f) **[0213]** a combination of the six most immunodominant targets (F + N + M2-1 + M + P + L)
- (g) **[0214]** a combination of the seven most immunodominant targets (F + N + M2-1 + M + P + L + G)
- (h) **[0215]** a combination of the eight most immunodominant targets (F + N + M2-1 + M + P + L + G + SH)
- (i) **[0216]** a combination of the nine most immunodominant targets (F + N + M2-1 + M + P + L + G + SH + M2-2)

### EXAMPLE 3

#### IDENTIFYING THE HIERARCHY OF IMMUNODOMINANCE FOR PIV3

**[0217]** Human parainfluenza virus type 3 (PIV3) is a respiratory tract pathogen and is a major cause of bronchiolitis and pneumonia in infants and very young children (Zvirbliene A. et al. Viral Immunology 2009). In addition to young children, PIV3 poses a threat to the elderly and to immunocompromised adults. PIV3 infection also causes severe illness leading to death (35% - 75%) in patients receiving hematopoietic stem cell transplant (HSCT) (Nichols WG et al. Blood 2001; Maziarz RT et al. Biol Blood Marrow Transplant 2010; Sasaki M et al. Emerging Infect. Dis. 2013)

#### **[0218] Virology**

**[0219]** PIV3 is a representative of the genus *Respirovirus* of the family *Paramyxoviridae*. It is an enveloped RNA virus containing a single-stranded RNA genome of negative polarity. The PIV3 genome contains approximately 15,500 nucleotides organized to encode at least six structural proteins in the invariant order N-P-M-F-HN-L (FIG. 20).

**[0220]** Infection of the host cell by PIV3 is initiated by binding of the hemagglutinin-neuraminidase (HN) glycoprotein on the virion envelope to sialic acid on cellular membrane proteins. The fusion (F) protein then mediates the fusion between the viral envelope and the host-cell plasma membrane. This releases the viral nucleocapsid, which consists of the viral genome

tightly bound by the nucleoprotein (N) and associated with the phosphoprotein (P) and the large RNA-dependent RNA polymerase (L) protein. The nucleocapsid-bound polymerase directs copying of the viral genes into separate mRNA transcripts and also directs replication of the RNA genome. Progeny nucleocapsids assemble and are packaged into virions that bud from plasma membrane. The matrix (M) protein coats the inner surface of the envelope and the spike-like glycoproteins F and HN project from the outer surface of the envelope (Schmidt AC et al. Expert Rev Respir. Med. 2012)

#### **[0221] Transmission**

**[0222]** Viral transmission occurs by direct inoculation of contagious secretions from hands or of large particle aerosols into the eyes, nose, or, rarely, the mouth (Maziarz RT et al. Biol Blood Marrow Transplant 2010). Replication of PIV3 occurs in the superficial epithelial cells lining the respiratory tract. Infection typically starts in the mucous membranes of the nose and throat but an infectious virus may also be transmitted directly to the lower respiratory tract (LRT) (Schmidt AC et al. Expert Rev Respir. Med. 2012).

#### **[0223] Epidemiology and Clinical Features**

**[0224]** Approximately 18,000 infants and children are hospitalized each year in the United States because of lower respiratory tract infections (LRTIs) caused by PIV3. Bronchiolitis and pneumonia are the most common clinical presentations (Henrickson KJ Clin. Microbiology Rev. 2003). In addition to young children, PIV3 is highly problematic in immunocompromised children and adults like transplant recipients. For example, between 5-7% of adult HSCT recipients become infected with PIV3; approximately 24-50% of whom develop severe LRTIs like pneumonia and 22-75% of these patients die from respiratory failure (Henrickson KJ Clin. Microbiology Rev. 2003). A retrospective study found that 25% of pediatric HSCT patients with PIV3 infection developed pneumonia and 33% died from it (Lujan-Zilbermann J et al. Clin Infect. Dis. 2001). Similarly, PIV3 has been shown to cause serious LRTIs and death (8%) in lung transplant recipients up to 5 years after transplantation (Vilchez RA. et al. Clin Infect. Dis. 2001).

#### **[0225] Prevention and Treatment**

**[0226]** Current approaches to PIV3 vaccines include intranasal administration of live attenuated strains, subunit strategies using the HN and F proteins, recombinant bovine/human

viruses, and strains engineered using reverse genetics. In fact, two investigational vaccines, rhPIV3<sub>cp45</sub> (or MEDI-560) an attenuated strain of PIV3 developed by cold passage, and B/hPIV3-RSV-F (or MEDI-534) a cDNA-derived chimeric bovine/human PIV3, are currently being tested in Phase I clinical trials. Analysis of safety and immunogenicity data is pending (Schmidt AC et al. Expert Rev Respir. Med. 2012).

**[0227]** Agents found to have *in vitro* antiviral activity against paramyxoviruses including PIV3 include neuraminidase inhibitors (*e.g.*, zanamivir), protein synthesis inhibitors (puromycin), nucleic acid synthesis inhibitors, benzthiazole derivatives, 1,3,4-thiadiazol-2-ylcyanamide, carbocyclic 3-deazaadenosine, ascorbic acid, calcium elenolate and extracts of *Sanicula europaea*. None of these compounds or drugs have yet found clinical applications (Henrickson KJ Clin. Microbiology Rev. 2003).

**[0228]** Ribavirin is a guanosine analog used to stop viral RNA synthesis and viral mRNA capping. Anecdotal reports of decreased PIV3 shedding and clinical improvement have been reported in immunocompromised patients treated with aerosolized and oral ribavirin. However, a recent review at Fred Hutchinson Cancer Center demonstrated that established PIV3 pneumonias responded poorly to aerosolized ribavirin (Nicholas WG et al. Biol. Blood Marrow Transpl. 2001). Currently there are no antiviral drugs with proven clinical efficacy against PIV3 (Henrickson KJ Clin. Microbiology Rev. 2003).

#### **[0229] Immune Response and Correlates of Protection**

**[0230]** PIV3 infections can induce potent humoral and cellular immune responses in the infected host. Both serum and mucosal neutralizing antibodies can provide lasting protection against disease (Schmidt AC et al. Expert Rev Respir. Med. 2012). Similarly, Cytotoxic T-lymphocyte responses appear to be important in the clearance of virus from the LRT during infections with PIV3 (Henrickson KJ Clin. Microbiology Rev. 2003). Therefore assessing the immunodominant hierarchy of PIV3 is necessary to develop new therapeutic strategies.

#### **[0231] Establishing a hierarchy of immunodominance for PIV3**

**[0232]** Applying the process and TC-test described in Example 1, the following represents a novel characterization of T cell response for PIV3:

**[0233]** PIV3 was compartmentalized into the following fragments: HN, Protein C, PP, Large, M, N and Fusion. The percentage of responders were 88.2% for HN, 47% for Protein C, 47% for PP, 47% for Large, 94.1% for M, 64.7% for N and 47% for Fusion and the magnitude of response was 131 for HN, 214.6 for Protein C, 203.7 for PP, 115.8 for Large, 261.2 for M, 160 for N and 175.7 for Fusion. Applying the TC-test, we identified a TC-score of 912.91 for HN, 190.76 for Protein C, 181.07 for PP, 102.93 for Large, 3600 for M, 289.59 for N and 156.18 for Fusion (FIGS. 21 and 22). Applying the TC-score, the inventors ranked the different PIV3 antigens as follows (FIG. 23):

**[0234]**  $M > HN > Large > N > Protein\ C > PP > Fusion > Large$

**[0235]** Hence, in order to provide protective immunity to a patient infected with PIV3, the following represents the identification of desired target or combination of targets (FIG. 13):

- (a) **[0236]** the most immunodominant target antigen (Antigen M)
- (b) **[0237]** a combination of the two most immunodominant targets (M + HN)
- (c) **[0238]** a combination of the three most immunodominant targets (M + HN + N)
- (d) **[0239]** a combination of the four most immunodominant targets (M + HN + N + Protein C)
- (e) **[0240]** a combination of the five most immunodominant targets (M + HN + N + Protein C + PP)
- (f) **[0241]** a combination of the six most immunodominant targets (M + HN + N + Protein C + PP + Fusion)
- (g) **[0242]** a combination of the seven most immunodominant targets (M + HN + Large + N + Protein C + PP + Fusion + Large)

#### EXAMPLE 4

##### IDENTIFICATION OF PERCENTAGE OF RESPONDERS

**[0243]** As shown in FIGS. 18 and 22, and as an example, the threshold of IFN $\gamma$  production can be used to identify a critical level of T cell activity that can be used to determine



responders *vs.* non-responders. However, one skilled in the art will recognize that this threshold is not exclusive to IFN $\gamma$  production and can be substituted by any other biological marker produced (as in secreted by the cells and measured from the supernatant of a culture of cells) or expressed (as in a non-soluble marker fixed on a cellular membrane) by T cells upon the recognition with a relevant target including but not limited to IL2, Granzyme B, CD25, GM-CSF, and TNF $\alpha$ , for example. All such markers can be used to determine responders *vs.* non-responders by first identifying a threshold of unspecific response. The level of unspecific response can be identified by the magnitude of biological activity detected against an irrelevant antigen (*e.g.*, an antigen not used in the initial T cell stimulation). For example, when analyzing the immune response to a virus encoding 5 antigens (A, B, C, D, E) an irrelevant antigen would be antigen F derived from a different virus or against unmanipulated PBMCs. This has been determined as 20 SFC per  $2 \times 10^5$  for IFN $\gamma$  and 10 SFC per  $2 \times 10^5$  for Granzyme B, in specific embodiments. FIG. 24 shows an example where Granzyme B is used to determine a percentage of responders *vs.* non-responders for the characterization of an immune response against a pathogen.

## EXAMPLE 5

### TC-SCORE IDENTIFIES CLINICALLY RELEVANT TARGETS

[0244] To confirm the clinical relevance of the hierarchy established by the TC-score, the inventors analyzed the immune T cell response against PIV3 in a patient with active infection. As shown in FIG. 25, the frequency of PIV3-specific T cells targeting antigens M and N exhibit a particular enrichment between Day 155 and Day 162, correlating with a subsequent improvement in clinical symptoms, which subsided by Day 167. Another example of clinical relevance of PIV3 T cells to control viral infection is shown in FIG. 26, where an increase in the frequency of PIV3-specific T cells had an inverse correlation with the symptoms of infection and viral detection by PCR present in a single representative patient with active infection post bone marrow transplant (BMT).

[0245] FIG. 27 illustrates the clinical relevance of the immune T cell response against different hMPV antigens. This figure shows the frequency of T cells reactive against proteins F, N, M, M2-1 and P detected in a single representative patient with active HMPV infection, whose symptoms resolved after detection of these T cells in peripheral blood.

**[0246] Targeting top-ranked antigens using T-cells**

**[0247]** FIGS. 28, 29, and 30 illustrate the therapeutic application of this ranking where the top targets of a given pathogen or cancer are identified as a source of antigen. Culture conditions with this will then result in a subsequent enrichment of T cells specific for the given targets.

**[0248] Generation of PIV3-specific T cells for therapeutic use**

**[0249]** PBMCs isolated from healthy PIV3-seropositive individuals were cultured with peptides overlapping the entire proteins M and HN in the presence of Th1-polarizing cytokines for a period of 10 days. FIG. 31 shows the phenotypic characteristics of a T cell product and FIG. 32 shows the antigen specificity of CD4+ and CD8+ as detected by intracellular cytokine staining for antigens M and HN.

**[0250] Generation of hMPV-specific T cells for therapeutic use**

**[0251]** PBMCs isolated from healthy hMPV-seropositive individuals were cultured with peptides overlapping the entire protein in the presence of Th1-polarizing cytokines using the G-Rex culture system (or any other cell culture platform, bioreactor or tissue culture plates) for a period of 10 days as illustrated in FIG. 33. This process resulted in the significant expansion of T cells as illustrated in FIG. 34. Upon examination, these expanded cells were polyclonal (FIG. 35) and found to be antigen-specific as detected by intracellular cytokine staining for relevant antigens (FIG. 37). To evaluate the antiviral properties of this expanded T cell product, HLA matched target cells were pulsed with HMPV peptides and labeled with PKH dye and cultured at a 1:1 ratio with HMPV-specific T cells. As shown in FIG. 36, the culture with virus-specific T cells resulted in a progressive decline in the HMPV target cells from 35.5% to 18.7% to 6.4% after Day 0, 2 and 4 of culture. Therefore, as time progresses, there is killing of infected cells.

**EXAMPLE 6****IDENTIFICATION OF CLINICAL EFFICACY FOR A PRODUCT****[0252] Product composition**

**[0253]** The inventors have identified examples of biological features of a final product that correlate with clinical efficacy, in certain embodiments.

[0254] In specific embodiments, the following description of how to identify if a product will have clinical efficacy in a patient is unrelated to other embodiments herein that concern determination of hierarchy of immunogenicity of antigens for a pathogen. That is, T cells having certain antigens may be subjected to the characterization methods below whether or not their respective antigen was selected based on an immunogenic hierarchy or was based on other methods of antigen selection, or is random.

**[0255] Characterization of virus-specific T cells**

[0256] *Identity:* In some cases, the identity of the cells may be determined by HLA typing. The final product comprises donor-derived cells, in at least some cases. Therefore, the HLA type of the final product should be identical to that of the donor blood in certain embodiments.

[0257] *Phenotypic analysis:* Optimal *in vivo* T cell persistence and activity requires both helper (CD4<sup>+</sup>) and cytotoxic (CD8<sup>+</sup>) T cells. Phenotypic analysis may therefore be used to determine if product is comprised of polyclonal T cells.

[0258] *Specificity:* The antiviral specificity of product can be assessed *in vitro* by exposing the expanded cells to each of the individual synthetic peptide libraries and assessing their capacity to recognize each of the synthetic peptide libraries. For example, one method to assess product specificity involves testing the ability of these cells to produce cytokine interferon gamma (IFN $\gamma$ ) following synthetic peptide exposure using an IFN $\gamma$  ELISpot test. In this test, cells are re-exposed to each of the viral antigens used for stimulation. Product is considered specific for Virus X when the sum of IFN $\gamma$ -producing spot-forming cells (SFCs) directed against all antigens from target virus was  $\geq 20$  SFCs per  $2 \times 10^5$  input cells (as an example of a threshold of activity).

[0259] *Cytotoxicity:* The cytotoxic specificity of product can be measured in a standard killing assays, where cells are used as effectors and the targets are, for example, chromium-labeled PHA blasts pulsed with the relevant pepmixes. Effector to target ratios may be (or may be at least or no more than): 5:1, 10:1, 15:1, 20:1, 25:1, 30:1, 35:1, 40:1, 45:1, 50:1, 55:1, 60:1, 65:1, 70:1, 75:1, 80:1, 85:1, 90:1, 95:1, *etc.* Autologous or allogeneic PHA blasts alone or loaded with irrelevant pepmixes can be used as specificity and alloreactivity controls. For example, a pProduct is considered to show cytotoxicity specificity against Virus X if the

percentage of specific lysis of PHA blasts pulsed with relevant pepmixes is  $\geq 10\%$  at a 40:1 Effector effector to target ratio, in at least certain cases. Killing of target cells at a given effector to target ratio is considered antigen-specific when above a baseline level (established using either unmanipulated PBMCs as effectors or assessing the activity of the T cell product against target cells pulsed with an irrelevant antigen).

**[0260]** The following represents a mathematical representation that allows one skilled in the art to identify a product composition:

**[0261] Product definition**

**[0262]** The product is defined as T cells isolated from *in vitro* culture characterized by:

**[0263]**  $({}_R\text{TB}) + ({}_R\text{TK}) \geq 1$

- **[0264]** where  ${}_R\text{TB}$  is defined as  $[(\text{Tbio-P}) + 1] / [(\text{Tbio-U}) + 1]$ , which when  $\geq 1$  will be equivalent to an  ${}_R\text{TB}$  value of 1 and when  $< 1$  will correspond to an  ${}_R\text{TB}$  value of 0; and
- **[0265]**  ${}_R\text{TK}$  is defined as  $[(\% \text{TSpec-P}) / \text{TCSpec}]$ , which when  $\geq 1$  will be equivalent to an  ${}_R\text{TK}$  value of 1 and when  $< 1$  will correspond to an  ${}_R\text{TK}$  value of 0 (see FIG. 38).

**[0266]** Tbio-P is defined as the biological activity of the *in vitro* T cell product and Tbio-U is the biological activity of the noise threshold, which as previously described can be the biological activity of unmanipulated PBMCs when in the presence of an antigen of interest or the biological activity of the *in vitro* T cell product when in the presence of an irrelevant antigen that is not of interest. Such biological activity could include, but is not limited to,  $\text{IFN}\gamma$ , IL2, GM-CSF and  $\text{TNF}\alpha$  production for example and the upregulation of markers such as CD25, CD45, CD27, CD28, CD69 and CD107 for example.

**[0267]** TSpec-P, or the specific killing ability of the *in vitro* T cell product, is defined as the percentage of lysed HLA-matched target cells expressing the cognate antigen at a predefined effector to target ratio, (e.g., 40:1 effector to target ratio) after subtracting the percentage of unspecific killing by unmanipulated PBMCs of target cells expressing an irrelevant peptide, *i.e.* an antigen or marker not present within the pathogen or tumor of interest at a predefined effector to target ratio.

[0268] In the event that multiple products are available for clinical administration, the supplemental formula  $[\alpha(\text{RTB}) + \beta(\text{RTK}) = \phi]$  can be applied to rank products in order of preference.

$$[0269] \alpha(\text{RTB}) + \beta(\text{RTK}) = \phi$$

$$[0270] \text{Where } {}_{\text{RTB}} \text{ is defined as the value resulting from } [(T_{\text{bio-P}}) + 1] / [(T_{\text{bio-U}}) + 1]$$

$$[0271] \text{Where } {}_{\text{RTK}} \text{ is defined as the value resulting from } [(\% \text{ TSpec-P}) / \text{TCSpec}]$$

[0272] where  $\alpha$  and  $\beta$  are defined as weighting coefficients dependent upon variables including but not limited to therapeutic applications, manufacturing processes, peptide mixtures, cell lines, *etc.*

[0273] where  $\phi$  is defined as a clinical efficacy value that may be used to determine a ranking of clinical efficacy among therapeutic products

[0274] **Example 1** is an example of biological characteristics present in a product.

$$[0275] T_{\text{bio-P}} = 200 \text{ SFC per } 2 \times 10^5 \text{ IFN}\gamma$$

$$[0276] T_{\text{bio-U}} = 50 \text{ SFC per } 2 \times 10^5 \text{ IFN}\gamma$$

$$[0277] \text{TSpec-P} = 40\%$$

$$[0278] \text{TCSpec} = 10\%$$

$$[0279] \alpha = 1$$

$$[0280] \beta = 5$$

$$[0281] {}_{\text{RTB}} = [(T_{\text{bio-P}}) + 1] / [(T_{\text{bio-U}}) + 1]$$

$$[0282] {}_{\text{RTB}} = [(200) + 1] / [(50) + 1] = 3.94$$

[0283] Therefore,

$$[0284] {}_{\text{RTB}} = 1$$

$$[0285] {}_{\text{RTK}} = [(\text{TSpec-P}) / (\text{TCSpec})]$$

$$[0286] \text{ } _{\text{R}}\text{TK} = [(40\%) / (10\%)] = 4$$

[0287] Therefore,

$$[0288] \text{ } _{\text{R}}\text{TK} = 1$$

[0289] Therefore, this example constitutes a product as defined by  $(\text{ } _{\text{R}}\text{TB}) + (\text{ } _{\text{R}}\text{TK}) \geq 1$ . In addition, the clinical efficacy of this product is 23.94 as defined by  $\alpha(\text{ } _{\text{R}}\text{TB}) + \beta(\text{ } _{\text{R}}\text{TK}) = \phi$ .

[0290] **Example 2** is an example of biological characteristics present in a product.

$$[0291] \text{ Tbio-P} = 100 \text{ SFC per } 2 \times 10^5 \text{ Granzyme B}$$

$$[0292] \text{ Tbio-U} = 10 \text{ SFC per } 2 \times 10^5 \text{ Granzyme B}$$

$$[0293] \text{ TSpec-P} = 5\%$$

$$[0294] \text{ TCSpec} = 10\%$$

$$[0295] \alpha = 1$$

$$[0296] \beta = 5$$

$$[0297] \text{ } _{\text{R}}\text{TB} = [(\text{Tbio-P}) + 1] / [(\text{Tbio-U}) + 1]$$

$$[0298] \text{ } _{\text{R}}\text{TB} = [(100) + 1] / [(10) + 1] = 9.18$$

[0299] Therefore,

$$[0300] \text{ } _{\text{R}}\text{TB} = 1$$

$$[0301] \text{ } _{\text{R}}\text{TK} = [(\text{TSpec-P}) / (\text{TCSpec})]$$

$$[0302] \text{ } _{\text{R}}\text{TK} = [(5\%) / (10\%)] = 0.5$$

[0303] Therefore,

$$[0304] \text{ } _{\text{R}}\text{TK} = 0$$

[0305] Therefore, Example 2 constitutes a product as defined by  $(\text{ } _{\text{R}}\text{TB}) + (\text{ } _{\text{R}}\text{TK}) \geq 1$ . In addition, the clinical efficacy of this product is 11.68 as defined by  $\alpha(\text{ } _{\text{R}}\text{TB}) + \beta(\text{ } _{\text{R}}\text{TK}) = \phi$ .

[0306] Because Examples 1 and 2 both constitute a product as defined by  $(R_{TB}) + (R_{TK}) \geq 1$ , the clinical efficacy value ( $\phi$ ) will aid in determining product selection if a patient is eligible to receive both products from Example 1 and 2. A greater  $\phi$  value represents a product with higher specificity and killing ability and therefore, products can be ranked. In this case, Example 1 constitutes a 'superior' product for administration to a patient based on its  $\phi$  clinical efficacy variable.

[0307] **Example 3** is an example of biological characteristics not present in a product.

[0308]  $T_{bio-P} = 50$  SFC per  $2 \times 10^5$  IL2

[0309]  $T_{bio-U} = 70$  SFC per  $2 \times 10^5$  IL2

[0310]  $T_{Spec-P} = 9\%$

[0311]  $T_{Spec} = 10\%$

[0312]  $\alpha = 1$

[0313]  $\beta = 5$

[0314]  $R_{TB} = [(T_{bio-P}) + 1] / [(T_{bio-U}) + 1]$

[0315]  $R_{TB} = [(50) + 1] / [(70) + 1] = 0.7$

[0316] Therefore,

[0317]  $R_{TB} = 0$

[0318]  $R_{TK} = [(T_{Spec-P}) / (10\%)]$

[0319]  $R_{TK} = [(9\%) / (10\%)] = 0.9$

[0320] Therefore,

[0321]  $R_{TK} = 0$

[0322] Therefore, Example 3 does not constitute a product as defined by  $(R_{TB}) + (R_{TK}) \geq 1$ .

## EXAMPLE 7

## PRODUCT MANUFACTURE

[0323] A product defined as *in vitro* T cells characterized by  $(R_{TB}) + (R_{TK}) \geq 1$  can be attained through various manufacturing processes. The description below concerns embodiments for the determination of whether or not certain T cells are therapeutically useful. The following represent some manufacturing examples:

**[0324] 1. Manufacture and Cryopreservation of Virus-specific T cells**

[0325] Mononuclear cells from peripheral blood or leukapheresis product from healthy donors are contacted with one or more overlapping synthetic peptide libraries encompassing all or part of the sequence of one or more of the antigens expressed by Virus X. Following synthetic peptide exposure antigen-specific T cells within mononuclear cells are activated and expand in an *in vitro* manufacturing process. In this example, Mononuclear cells will be activated and expanded for 9-11 days *in vitro* by adding them to a gas-permeable culture device (such as a G-Rex culture device) or tissue culture plates along with T cell media supplemented with the Th1 cytokines such as but not limited to IL7 and IL4 and clinical grade peptide mixtures (pepmixes) spanning the entire sequence of one or more antigens of Virus X. In addition to clinical grade peptide mixtures (pepmixes), one skilled in the art will recognize that the source of antigen could also include, for example, recombinant proteins, DNA, RNA encoding for an antigen(s), and so forth of the virus. In specific cases, the product meets the criteria set by  $(R_{TB}) + (R_{TK}) \geq 1$ , therefore it can be cryopreserved for future clinical use, for example.

[0326] Alternatively, additional antigen stimulations can be performed (on days 10-13 of culture) where antigen presenting cells that can either be autologous mononuclear cells (or) OKT3 blasts (or) PHA blasts (as examples) are pulsed again with the pepmixes specific for one or more antigens of Virus X and then irradiated (80Gy) and subsequently used as stimulators. At the time of the 2nd stimulation cultures will be supplemented Th1 cytokines (such as but not limited to IL4+IL7, IL15, IL2, IL21, IL12 or combinations thereof) and 3 days later cultures are supplemented with IL2, or IL15, IL7, IL21, IL4 or combinations thereof. After 19-23 days in culture, cells specific for Virus X are harvested from the G-Rex culture device or tissue culture plates, pooled into appropriately-sized sterile containers and counted. The cells are washed by centrifugation and are then re-suspended in ice cold freezing medium up to a concentration of



$1 \times 10^7$  cells/mL, in suitable aliquots for patient infusion. At this time, or within 7 days of freezing, an appropriate number of cells, culture supernatants pre and post washes, and aliquots of final cell suspension may be submitted for endotoxin testing and microbiological screens. At the same time, an appropriate number of cells may be taken for product characterization that includes HLA typing, phenotypic, specificity and/or cytolytic function, for example.

**[0327]** In specific embodiments, the time following the first antigen stimulation until the second antigen stimulation (see FIGS. 39-41 as examples) may be any suitable time and may vary depending on a variety of reasons, such as the antigen being utilized, for example. In particular embodiments the number of days between the first antigen stimulation and the second antigen stimulation is (or is at least or no more than) 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 25, 30, 35, 40, 45, 50, or more days. In other embodiments, the time following the second antigen stimulation may be any suitable time and may vary depending on a variety of reasons, such as the antigen being utilized, for example. In particular embodiments the number of days between the second antigen stimulation and a subsequent step (such as an endpoint for the culture, a testing of the cells, a therapeutic use of the cells, and so forth) is (or is at least or no more than) 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 25, 30, 35, 40, 45, 50, or more days.

## **[0328] 2. Characterization of virus-specific T cells**

**[0329]** *Identity:* The identity of the cells will be determined by HLA typing. The final product consists of donor-derived cells. Therefore the HLA type of the final product should be identical to that of the donor blood.

**[0330]** *Phenotypic analysis:* Optimal *in vivo* T cell persistence and activity requires both helper (CD4<sup>+</sup>) and cytotoxic (CD8<sup>+</sup>) T cells. Phenotypic analysis is therefore used to determine if product is composed of polyclonal T cells.

**[0331]** *Specificity:* The antiviral specificity of product can be assessed *in vitro* by exposing the expanded cells to each of the individual synthetic peptide libraries and assessing their capacity to recognize each of the synthetic peptide libraries. For example, one method to assess product specificity involves testing the ability of these cells to produce cytokine interferon gamma (IFN $\gamma$ ) following synthetic peptide exposure using an IFN $\gamma$  ELISpot test. In this test cells are reexposed to each of the viral antigens used for stimulation. Product is considered specific for

Virus X when the sum of IFN $\gamma$ -producing spot-forming cells (SFCs) directed against all antigens from target virus was  $\geq 20$  SFCs per  $2 \times 10^5$  input cells.

**[0332]** *Cytotoxicity*: The cytotoxic specificity of product can be measured in a standard killing assays, where cells are used as effectors and the targets are PHA blasts pulsed with the relevant pepmixes. Autologous or allogeneic PHA blasts alone or loaded with irrelevant pepmix can be used as specificity and alloreactivity controls. Product is considered to show cytotoxicity against Virus X if the percentage of specific lysis of PHA blasts pulsed with relevant pepmixes is  $\geq 10\%$  at a 40:1 Effector to target ratio.

### **[0333] 3. Data**

**[0334]** The methods for manufacture and characterization of T-cells specific for immunodominant antigens of a virus as described above were used to generate T-cells specific for Adenovirus (AdV), BK virus (BKV) and Cytomegalovirus (CMV), as examples only.

#### **[0335] 3.1 Adenovirus**

**[0336]** Adenovirus remains a major cause of morbidity and mortality in immunocompromised individuals, in whom it may produce pneumonia, hemorrhagic cystitis, nephritis, colitis, hepatitis, and encephalitis. The most frequently used drug for disease treatment is Cidofovir, but the clinical benefit in patients with overt viral disease is limited and the associated nephrotoxicity is a major concern. Moreover, in the absence of prospective, randomized, controlled trials, the efficacy of the drug remains uncertain (Leen AM et al. Biol. Blood Marrow Transpl. 2006). Given that viral clearance has been shown to correlate with the detection of circulating AdV-specific T cells adoptive T cell transfer has been considered as an alternative therapeutic option (Feuchtinger T. et al. Br. J. Hematol. 2005)

**[0337]** To generate Adenovirus-specific T cells, mononuclear cells from peripheral blood product from healthy donors were activated and expanded *in vitro* by adding them to a GRex culture device along with T cell media supplemented with the cytokines IL7 and IL4 and clinical grade peptide mixtures (pepmixes) spanning the entire sequence of the most immunodominant antigens of Adenovirus, namely Hexon and Penton. For the second stimulation (on days 10-13 of culture) autologous PBMCs were pulsed again with the pepmixes specific for Hexon and Penton and then irradiated (80Gy) and subsequently used as APCs followed by expansion in media supplemented with IL4 and IL7 and later supplemented with IL2. The specificity and cytolytic

capability of the cultures was assessed on Day 0, 10 and 20 as shown in FIG. 39. Compared to unmanipulated PBMCs on Day 0, cultures on Day 10 showed a substantial increase in the frequency of Hexon- and Penton-directed T cells (28.7 and 32.3 fold increase, respectively) as evidenced by >20 IFN $\gamma$ -producing SFCs. Cultures on Day 20 showed further increase in T cell specificity (2.7 and 1.9 fold increase in Hexon or Penton-reactive cells, respectively) over Day 10 cultures. Importantly the cultures on Day 20 contained cells that received a second stimulation which conferred the expanded cells with the ability to kill antigen-loaded target cells as evidenced by >10% cytotoxicity of Adenovirus antigen loaded target cells.

### **[0338] 3.2 BK virus**

**[0339]** BKV is a ubiquitous polyomavirus that establishes a latent, asymptomatic infection in >90% of the general population. In both solid organ and HSCT allograft recipients, however, viral reactivation is frequent and correlates with the absence of circulating BKV-specific T cells. Thus, urinary shedding of BKV occurs in 60-80% of HSCT recipients (Tomblyn M et al. Bone Marrow Transpl. 2009), and develops into BKV-associated hemorrhagic cystitis (PVHC) in 5-15%, resulting in prolonged hospital stays, severe morbidity and increased mortality. Currently there are still no approved antiviral agents for treatment of BK virus infection.

**[0340]** To generate BK virus-specific T cells, mononuclear cells from peripheral blood from healthy donors were activated and expanded *in vitro* by adding them to a GRex culture device along with T cell media supplemented with the cytokines IL7 and IL4 and clinical grade peptide mixtures (pepmixes) spanning the entire sequence of the most immunodominant antigens of BK virus, namely LT and VP1. For the second stimulation (on days 10-13 of culture) autologous PBMCs were pulsed again with the pepmixes specific for LT and VP1 and then irradiated (80Gy) and subsequently used as APCs followed by expansion in media supplemented with IL4 and IL7 and later supplemented with IL2. The specificity and cytolytic capability of the cultures was assessed on Day 0, 10 and 20 as described above and shown in FIG. 40. Compared to naïve cultures on Day 0, cultures on Day 10 showed a substantial increase in the frequency of LT and VP1-specific T cells (316.8 and 38.6 fold increase, respectively) as evidenced by >20 IFN $\gamma$ -producing SFCs. Cultures on Day 20 showed further increase in T cell specificity (2.7 and 1.9 fold increase in LT and VP1-reactive cells, respectively) over Day 10 cultures. Importantly these cultures contained cells that received a second stimulation which conferred the expanded

cells with the ability to kill antigen-loaded target cells as evidenced by >20% cytotoxicity of BK virus antigen loaded target cells.

### **[0341] 3.3 Cytomegalovirus**

**[0342]** Cytomegalovirus (CMV) is a latent beta-herpes virus that usually causes an asymptomatic infection in immunocompetent individuals. It persists in approximately 70% of healthy adults and replicates in epithelial cells, fibroblasts and monocytes. Reactivation of CMV in the stem cell recipient can result in significant morbidity and mortality, with clinical manifestations including interstitial pneumonitis, gastroenteritis, fevers, hepatitis, encephalitis and retinitis (Boeckh M et al. Biol. Blood Marrow Transpl. 2003). Cell-mediated immunity is considered the most important factor in controlling CMV infection and CMV-specific CD4+ and CD8+ lymphocytes play an important role in immune protection from both primary infection and subsequent reactivations.

**[0343]** To generate CMV-specific T cells, mononuclear cells from peripheral blood from healthy donors were activated and expanded *in vitro* by adding them to a GReX culture device along with T cell media supplemented with the cytokines IL7 and IL4 and clinical grade peptide mixtures (pepmixes) spanning the entire sequence of the most immunodominant antigens of CMV, namely IE1 and pp65. For the second stimulation (on days 10-13 of culture) autologous PBMCs were pulsed again with the pepmixes specific for IE1 and pp65 and then irradiated (80Gy) and subsequently used as APCs followed by expansion in media supplemented with IL4 and IL7 and later supplemented with IL2. The specificity and cytolytic capability of the cultures was assessed on Day 0, 10 and 20 as described above and shown in FIG. 41. Compared to naïve cultures on Day 0, cultures on Day 10 showed a substantial increase in the frequency of IE1 and pp65 (6.66 and 5.7 fold increase, respectively) as evidenced by >20 IFN $\gamma$ -producing SFCs. Cultures on Day 20 showed further increase in T cell specificity (1.1 and 1.4 fold increase in IE1 and pp65-reactive cells, respectively) over Day 10 cultures. Importantly these cultures contained cells that received a second stimulation which conferred the expanded cells with the ability to kill antigen-loaded target cells as evidenced by >20% cytotoxicity of CMV antigen loaded target cells.

**[0344]** In this section the manufacture and characterization of T cells specific for one or more immunodominant antigens of a virus is described. By providing 3 examples – AdV, BK virus and CMV - the inventors have shown that this process is robust and reproducible. In

addition, this process allows one to generate virus-specific T cells that have a specificity of >20 IFN $\gamma$  SFCs against the immunodominant antigens and a cytotoxicity of >10% that is predominantly attributable to a second stimulation included in the manufacturing process. This process can be therefore used to generate and characterize T cells specific for any viruses, including hMPV and PIV3 as previously described.

#### **[0345] 4. Scope**

**[0346]** Antigen-specific T cells manufactured and characterized by the process described above can be utilized in both a donor specific and 3<sup>rd</sup> party setting. The two are described in detail below:

##### **[0347] 4. 1 Donor specific setting**

**[0348]** In this setting, antigen-specific T cells are generated from peripheral blood or leukapheresis product following steps as outlined in section 1. These cells can then be administered to the patient. This is outlined in FIG. 42.

##### **[0349] 4. 2 Third-party setting**

**[0350]** In this setting, antigen-specific T cells are generated and cryopreserved from peripheral blood or leukapheresis product following similar steps as outlined in section 1. These cells can then be administered to a number of partially HLA-matched recipients as outlined in FIG. 43.

#### **[0351] Use of Product**

**[0352]** The following description concerns how to determine whether or not a product is therapeutically useful. In specific embodiments, the use of the product may be defined by:

**[0353]**  $[(R_{TB}) + (R_{TK})] \times Th$ , which when  $\geq 1$  is administered to a patient and when  $< 1$  is not administered.

**[0354]** In this equation,

**[0355]**  $Th = HLA_P \text{ vs } HLA_{Pt}$  (the number of shared alleles) which when  $\geq 1$  is equivalent to Th value of 1 and when  $< 1$  corresponds to a Th value of 0

[0356]  $HLA_P$  = the HLA type of the product

[0357]  $HLA_{Pt}$  = the HLA type of the patient

[0358] **Example 1** illustrates a scenario where a product will be administered to a specific patient.

[0359]  $T_{bio-P} = 212$  SFC per  $2 \times 10^5$  IL2

[0360]  $T_{bio-U} = 44$  SFC per  $2 \times 10^5$  IL2

[0361]  $T_{Spec-P} = 5\%$

[0362]  $T_{C_{Spec}} = 10\%$

[0363]  $R_{TB} = [(T_{bio-P}) + 1] / [(T_{bio-U}) + 1]$

[0364]  $R_{TB} = [(212) + 1] / [(44) + 1] = 4.7$

[0365] Therefore,

[0366]  $R_{TB} = 1$

[0367]  $R_{TK} = [(T_{Spec-P}) / (T_{C_{Spec}})]$

[0368]  $R_{TK} = [(5\%) / (10\%)] = 0.5$

[0369] Therefore,

[0370]  $R_{TK} = 0$

[0371]  $HLA_P = A(2,31), B(35,51), DR(3,4), DQ(2,4)$

[0372]  $HLA_{Pt} = A(2,11), B(27,35), DR(4,8), DQ(3,4)$

[0373]  $HLA_P$  vs  $HLA_{Pt} = 4$

[0374] Therefore,  $Th = 1$

[0375]  $[(R_{TB}) + (R_{TK})] \times Th$

[0376]  $[(1) + (0)] \times 1 = 1$

[0377] Therefore, this product will be administered to this particular patient.

[0378] **Example 2** illustrates a scenario where a product will be administered to a specific patient.

[0379]  $T_{bio-P} = 500 \text{ SFC per } 2 \times 10^5 \text{ IL2}$

[0380]  $T_{bio-U} = 10 \text{ SFC per } 2 \times 10^5 \text{ IL2}$

[0381]  $T_{Spec-P} = 55\%$

[0382]  $T_{C_{Spec}} = 10\%$

[0383]  $R_{TB} = [(T_{bio-P}) + 1] / [(T_{bio-U}) + 1]$

[0384]  $R_{TB} = [(500) + 1] / [(10) + 1] = 45.5$

[0385] Therefore,

[0386]  $R_{TB} = 1$

[0387]  $R_{TK} = [(T_{Spec-P}) / (T_{C_{Spec}})]$

[0388]  $R_{TK} = [(55\%) / (10\%)] = 5.5$

[0389] Therefore,

[0390]  $R_{TK} = 1$

[0391]  $HLA_P = A(2,24), B(8,14), DR(1,3), DQ(2,5)$

[0392]  $HLA_{Pt} = A(2,23), B(15,44), DR(7,13), DQ(3,3)$

[0393]  $HLA_P \text{ vs } HLA_{Pt} = 1$

[0394] Therefore,  $Th = 1$

[0395]  $[(R_{TB}) + (R_{TK})] \times Th$

[0396]  $[(1) + (1)] \times 1 = 2$

[0397] Therefore, this product will be administered to this particular patient.

[0398] **Example 3** illustrates a scenario where a product will not be administered to a patient.

[0399]  $T_{\text{bio-P}} = 1200 \text{ SFC per } 2 \times 10^5 \text{ IL2}$

[0400]  $T_{\text{bio-U}} = 54 \text{ SFC per } 2 \times 10^5 \text{ IL2}$

[0401]  $T_{\text{Spec-P}} = 87\%$

[0402]  $T_{\text{CSpec}} = 10\%$

[0403]  $R_{\text{TB}} = [(T_{\text{bio-P}}) + 1] / [(T_{\text{bio-U}}) + 1]$

[0404]  $R_{\text{TB}} = [(1200) + 1] / [(54) + 1] = 21.8$

[0405] Therefore,

[0406]  $R_{\text{TB}} = 1$

[0407]  $R_{\text{TK}} = [(T_{\text{Spec-P}}) / (T_{\text{CSpec}})]$

[0408]  $R_{\text{TK}} = [(87\%) / (10\%)] = 8.7$

[0409] Therefore,

[0410]  $R_{\text{TK}} = 1$

[0411]  $HLA_P = A(1,24), B(8,14), DR(11,8), DQ(2,5)$

[0412]  $HLA_{Pt} = A(2,23), B(15,44), DR(7,13), DQ(3,3)$

[0413]  $HLA_P \text{ vs } HLA_{Pt} = 0$

[0414] Therefore,  $Th = 0$

[0415]  $[(R_{\text{TB}}) + (R_{\text{TK}})] \times Th$



**[0416]**  $[(1) + (1)] \times 0 = 0$

**[0417]** Therefore, this product will not be administered to this particular patient.

**[0418]** An example represents the clinical outcome of a patient with active CMV infection treated with a CMV-specific T cell product defined by  $(rTB) + (rTK) \geq 1$  and selected by  $[(rTB) + (rTK)] \times Th \geq 1$ . As shown in FIG. 45, following the administration of CMV-specific T cells there was a subsequent decrease in the viral load as detected by PCR in the peripheral blood of the patient, which had an inverse correlation with the increase of CMV-specific T cells as detected by IFN $\gamma$  ELISpot.

**[0419]** An example represents the clinical outcome of a patient with active viral infection treated with a EBV-specific T cell product defined by  $(rTB) + (rTK) \geq 1$  and selected by  $[(rTB) + (rTK)] \times Th \geq 1$ . As shown in FIG. 46, following the administration of EBV-specific T cells there was a subsequent decrease in the viral load as detected by PCR in the peripheral blood of the patient, which had an inverse correlation with the increase of EBV-specific T cells as detected by IFN $\gamma$  ELISpot.

**[0420]** This example represents the clinical outcome of a patient with active viral infection treated with a BKV-specific T cell product defined by  $(rTB) + (rTK) \geq 1$  and selected by  $[(rTB) + (rTK)] \times Th \geq 1$ . As shown in FIG. 47, following the administration of BKV-specific T cells there was a subsequent decrease in the viral load as detected by PCR in the urine of the patient, which had an inverse correlation with the increase of BKV-specific T cells as detected by IFN $\gamma$  ELISpot.

**[0421]** Although embodiments of the present invention and its advantages have been described in detail, it should be understood that various changes, substitutions and alterations can be made herein without departing from the spirit and scope of the inventions as defined by the appended claims. Moreover, the scope of the present application is not intended to be limited to the particular embodiments of the process, machine, manufacture, composition of matter, means, methods and steps described in the specification. As one of ordinary skill in the art will readily appreciate from the disclosure of the present invention, processes, machines, manufacture, compositions of matter, means, methods, or steps, presently existing or later to be developed that perform substantially the same function or achieve substantially the same result as the corresponding embodiments described herein may be utilized according to the present

inventions. Accordingly, the appended claims are intended to include within their scope such processes, machines, manufacture, compositions of matter, means, methods, or steps.

## CLAIMS

What is claimed is:

1. A method of obtaining information that can be used to determine the immunogenicity of antigens for a pathogen or cancer, comprising the steps of:

obtaining cells from a plurality of individuals,

exposing the cells *in vitro* to more than one antigen from a pathogen or cancer under conditions to allow cells that recognize the antigens to expand in quantity,

adding one of said antigens into separate cultures of the expanded cells,

comparing a determined magnitude of a biological activity to a threshold value to determine if the antigen is a responder or a non-responder, and

identifying the antigen as a responder if the biological activity exceeds the threshold.

2. The method of claim 1, wherein the pathogen is a virus, fungus, or bacteria.

3. The method of claim 1 or 2, wherein the biological activity comprises production of IFN $\gamma$ , IL2, Granzyme B, GM-CSF, and/or TNF $\alpha$ .

4. The method of any one of claims 1-3, further comprising the step of determining the threshold value.

5. The method of any one of claims 1-4, wherein the mathematical formula is the following:

$$\frac{(\% \text{ of responders} + 1) \times \text{Magnitude of Response}}{(\% \text{ of non-responders} + 1)}.$$

6. The method of claim 2, wherein the virus is a respiratory virus.

7. The method of claim 6, wherein the respiratory virus is a parainfluenza virus or metapneumavirus.

8. The method of claim 7, wherein the parainfluenza virus is type III.

9. The method of claim 7, wherein the metapneumavirus is human metapneumavirus.

10. The method of any one of claims 1-9, wherein the information is utilized in the determination of an immunotherapy for an individual that has been exposed to the pathogen, is at risk for exposure to the pathogen, is susceptible to the pathogen, has disease from the pathogen, is at risk for the cancer, or has the cancer.

11. The method of claim 10, wherein the immunotherapy comprises a vaccine, immunogenic composition, monoclonal antibody, bi-specific T-cell engager (BiTE), oncolytic virus, adoptive T cell transfer, or a combination thereof.

12. The method of claim 10, wherein the immunotherapy targets more than one antigen on the same cell.

13. A method of producing a T cell culture, comprising the steps of:

exposing PBMCs and/or T cells from a plurality of individuals to a part of a pathogen or tumor or a complete pathogen or tumor for at least 48 hours; followed by

re-challenge of the cells to individual antigens of the same pathogen or tumor.

14. The method of claim 13, wherein one or more biological measurements (Tbio) related to one or more changes in the cells in the culture and/or media from the culture are assayed.

15. The method of claim 14, wherein the one or more biological measurements measure one or more soluble products from the cells.

16. The method of claim 15, wherein the one or more soluble products are one or more cytokines.

17. The method of claim 16, wherein the one or more cytokines are selected from the group consisting of IL1 $\alpha$ , IL1 $\beta$ , IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12 (p35+p40), IL-13, IL-14, IL-15, IL-16, IL-17a, IL-17B, IL-17F, IL-18, IL-19, IL-20, IL-21, IL-22, IL-23 (p90+p43), IL-25, IL-26, IL-27 (p28 +EBI3), IL-28A/B/IL29A, IL-30 (p28 subunit of IL-27), IL-31, IL-32, IL-33, IL-35 (p35 + EBI3), TNF $\alpha$ , LT $\alpha$ , LT $\beta$ , LIGHT, OX40L, CD40L, FASL, CD27L, CD30L, 4-1BBL, TRAIL, RANK Ligand, GM-CSF, IFN $\gamma$ , LIF, MIF, TGF $\beta$ 1, TGF $\beta$ 2, TGF $\beta$ 3, and a combination thereof.

18. The method of claim 13, wherein the one or more biological measurements comprise one or more phenotypic changes identified intracellularly or on the cell surface of cells in the culture.

19. The method of claim 17, wherein cell surface phenotypical changes comprise expression and/or upregulation of CD11a, CD11c, CD16, CD25, CD27, CD28, CD31, CD38, CD40L, CD43, CD44, CD45, CD49d, CD62L, CD69, CD95, CD107, CD122, CD127, CXCR3, CCR5, CCR6, CCR7, KLRG-1 or a combination thereof.

20. The method of claim 17, wherein intracellular phenotypical changes comprise expression and/or upregulation of IL-1 $\beta$ , IL2, IL4, IL6, IL12, IL15, IL21, IFN $\alpha$ , IFN $\gamma$ , TNF $\alpha$ , TGF $\beta$ , CD107 and GM-CSF.

21. The method of any one of claims 13-19, wherein the biological measurements are performed after at least 15 minutes after exposing the culture to the individual pathogens/antigens.

22. The method of any one of claims 13-20, wherein the biological measurements are performed no later than 72 hours after exposing the culture to the individual pathogens/antigens.

23. The method of any one of claims 13-22, wherein a percentage of responders in the plurality of individuals for a given antigen of a pathogen or cancer cell can be determined by a mathematical relationship of a value of a biological measurement of the cells in the T cell culture and a value of a biological measurement of an unrelated target.

24. The method of claim 23, wherein the percentage of responders of a given antigen of a pathogen or cancer cell can be determined by dividing a value of the biological measurement of the cells in the T cell culture by a value of the biological measurement of an unrelated target.

25. The method of any one of claims 13-22, wherein a percentage of responders in the plurality of individuals for a given antigen of a pathogen or cancer cell can be determined by a mathematical relationship of a value of a biological measurement of the cells in the T cell culture and a value of a biological measurement of an unmanipulated T cell counterpart.

26. The method of claim 25, wherein the percentage of responders of a given antigen of a pathogen can be determined by dividing the value of biological measurement value of the cells in

the T cell culture by the value of a biological measurement of an unmanipulated T cell counterpart.

27. The method of claims 25 or 26, wherein the unmanipulated T cell counterpart comprises PBMCs.

28. The method of any one of claims 23-27, wherein an individual in the plurality is considered a responder when the determined result of the mathematical relationship is greater than or equal to 1.

29. The method of any one of claims 23-27, wherein an individual in the plurality is considered a non-responder when the determined result of the mathematical relationship is less than 1.

30. The method of any one of claims 23-29, wherein a threshold to determine a responder vs. a non-responder in a population is greater than 20 SFC per  $2 \times 10^5$  input cells when  $\text{IFN}\gamma$  production as measured in an ELISpot assay is the biological measurement.

31. The method of any one of claims 23-29, wherein a threshold to determine a responder vs. a non-responder in a population is greater than 10 SFC per  $2 \times 10^5$  input cells when Granzyme-B production as measured in an ELISpot assay is the biological measurement.

32. The method of any one of claims 13-31, wherein establishment of a hierarchy of antigens of a pathogen is obtained by combining the magnitude of the biological measurement value with a percentage of response against an antigen of a pathogen by evaluating 10 or more samples from seropositive individuals.

33. The method of any one of claims 13-32, wherein a relationship of a percentage and magnitude of responders to a biological measurement value is represented in a mathematical formula.

34. The method of claim 33, wherein the mathematical formula is

$$\frac{(\% \text{ of responders} + 1)}{(\% \text{ of non-responders} + 1)} \times \text{Magnitude of response (SFC}/2 \times 10^5)$$

35. The method of claim 33, wherein a product of the formula provides a score to each of the different antigens present in a pathogen or cancer.

36. The method of claim 35, wherein the score is utilized in establishment of hierarchy of immunodominance of one or more of the antigens of the pathogen or cancer.

37. The method of claim 36, wherein the hierarchy of immunodominance is used to select one or more antigens as a target.

38. The method of claim 36 or 37, wherein selection of one or more antigens comprises selection of:

- a) the first antigen in the hierarchy;
- b) the first with the second antigen in the hierarchy;
- c) the first with the third antigen in the hierarchy;
- d) the first with the fourth antigen in the hierarchy;
- e) the first with the second and third antigens in the hierarchy; or
- f) the first with the second and fourth antigens in the hierarchy.

39. The method of any one of claims 13-38, wherein the pathogen is a virus, fungus, or bacteria.

40. The method of claim 39, wherein the virus is PIV3 or hMPV.

41. The method of claim 40, wherein the pathogen is hMPV and the target antigen is the combination of F and N.

42. The method of claim 40, wherein the pathogen is PIV3 and the target antigen selection is one of the following:

- a) F;
- b) F and N;
- c) F and M2-1;
- d) F and M;

e) F, N, and M2-1; or

f) F, N and M

43. The method of any one of claims 36-42, wherein the antigens or combination of antigens identified in the hierarchy of immunodominance is used for a therapy.

44. The method of claim 43, wherein the therapy comprises a vaccine, monoclonal antibody, BiTE, oncolytic virus, adoptive cell therapy, or a combination thereof.

45. The method of any one of claims 13-44, wherein producing T cells targeting the one or more selected antigens comprises extraction of T cells from at least one healthy seropositive donor or patient.

46. The method of claim 45, wherein *ex vivo* manipulation of T cells comprises *in vitro* expansion of antigen-specific T cells.

47. The method of claim 46, wherein the antigen-specific T cells recognize the first antigen in the hierarchy of immunodominance of a pathogen or cancer cell.

48. The method of claim 46, wherein the antigen-specific T cells recognize the first and second antigen in the hierarchy of immunodominance of a pathogen or cancer cell.

49. The method of claim 46, wherein antigen-specific T cells recognize the first, second and third antigen in the hierarchy of immunodominance of a pathogen or cancer cell.

50. The method of claim 46, wherein antigen-specific T cells recognize first, second, third and fourth antigen in the hierarchy of immunodominance of a pathogen or cancer cell.

51. The method of any one of claims 46-50, wherein expanding antigen-specific T cells comprises the stimulation of antigen presenting cells (APCs) expressing the antigen(s) of interest.

52. The method of claim 51, wherein the antigen(s) comprise recombinant protein, overlapping peptides/peptide libraries, DNA encoding said antigen(s), RNA encoding said antigen(s), or viral vectors encoding said antigens.



53. The method of claim 51, wherein APCs used for antigen stimulation comprise B cells, T cells, macrophages, monocytes, PBMCs, or dendritic cells selected or expanded from autologous or allogeneic donors.

54. The method of claims 51-53, wherein APCs and antigen(s) are used alone or in combination with one or more cytokines.

55. The method of claim 54, wherein the one or more cytokines comprise IL2, IL4, IL7, IL12, IL15, and/or IL21.

56. The method of claims 51-55, wherein antigen stimulation is performed one or more times.

57. The method of claims 37-56, wherein antigen stimulation is performed at least once to obtain an antigen-specific T cell product.

58. The method of any one of claims 13-57, further comprising the step of determining a clinical value of the T cell product, wherein said determining comprises the formula  $({}_R\text{TB}) + ({}_R\text{TK}) \geq 1$ .

59. The method of Claim 58, wherein  ${}_R\text{TB}$  comprises  $[(\text{Tbio-P}) + 1] / [(\text{Tbio-U}) + 1]$  and when  $\geq 1$  is equivalent to an  ${}_R\text{TB}$  value of 1.

60. The method of Claim 58, wherein  ${}_R\text{TB}$  comprises  $[(\text{Tbio-P}) + 1] / [(\text{Tbio-U}) + 1]$  and when  $< 1$  is equivalent to an  ${}_R\text{TB}$  value of 0.

61. The method of Claim 58, wherein  ${}_R\text{TK}$  comprises  $[(\text{TSpec-P})/(\text{TCSpec})]$  and when  $\geq 1$  is equivalent to an  ${}_R\text{TK}$  value of 1.

62. The method of Claim 58, wherein  ${}_R\text{TK}$  comprises  $[(\text{TSpec-P})/(\text{TCSpec})]$  and when  $< 1$  is equivalent to an  ${}_R\text{TK}$  value of 0.

63. The method of any one of claims 59-60, wherein Tbio-P comprises one or more biological characteristics of an *in vitro* T cell product.

64. The method of any one of claims 59-60, wherein Tbio-U comprises one or more biological characteristics of unmanipulated PBMCs or irrelevant control.

65. The method of Claims 63-64, wherein the one or more biological characteristics comprise production of one or more cytokines or effector molecules and/or upregulation of one or more cell surface markers assessed upon stimulation with the cognate antigen.

66. The method of claim 65, wherein the cytokine /effector molecule is IFN $\gamma$ , IL2, GM-CSF, TNF $\alpha$ , Granzyme B, and/or perforin.

67. The method of claim 65, wherein the cell surface marker is CD25, CD45, CD27, CD28, CD69 and/or CD107.

68. The method of claim 61, wherein specific killing comprises the percentage of lysed HLA-matched target cells expressing a cognate antigen after subtracting the percentage of unspecific killing of target cells expressing an unrelated antigen.

69. The method of claim 68, wherein the unrelated antigen comprises an antigen not present within the pathogen or cancer cell of interest.

70. The method of claims 43-58, wherein administration of the T cells to an individual is a function of the formula  $[(R_{TB}) + (R_{TK})] \times Th$ , and when the value is  $\geq 1$  the T cells are administered to an individual, where  $Th$  is the number of shared alleles between a product and a patient.

71. The method of claims 43-58, wherein the administration of the T cells to an individual is a function of the formula  $[(R_{TB}) + (R_{TK})] \times Th$ , and when the value is  $< 1$  the T cells are not administered to an individual.

72. The method of claims 70 and 71, wherein  $Th = HLAP$  vs.  $HLAP_t$ , and when  $\geq 1$  is equivalent to  $Th$  value of 1.

73. The method of Claims 70 and 71, wherein  $Th = HLAP$  vs  $HLAP_t$  and when  $< 1$  corresponds to a  $Th$  value of 0.

74. The method of Claims 72 and 73, wherein  $HLAP$  is the HLA type of the product.

75. The method of Claims 72 and 73, wherein  $HLAP_t$  is the HLA type of the patient.





FIG. 1



256




FIG. 3




FIG. 4




FIG. 5




FIG. 6






FIG. 7




FIG. 8




FIG. 9




Fig. 10




FIG. 11




FIG. 12




FIG. 13




FIG. 14






FIG. 15




FIG. 16

T cell response to hMPV			
Antigen	(+) %	(-) %	Magnitude SFC/2x10 <sup>5</sup>
SH	3.4	96.6	34
M	79.3	20.7	154±24
L	44.8	55.2	125±22
G	31.0	69.0	62±18
F	96.5	3.5	300±52
M2-2	0	0	0
P	68.9	31.1	130±24
M2-1	79.3	20.7	167±21
N	86.2	13.8	220±33

FIG. 17

T cell response to hMPV				
Antigen	(+) %	(-) %	Magnitude SFC/2x10 <sup>5</sup>	TC-score rank
SH	3.4	96.6	34	1.53
M	79.3	20.7	154±24	569.87
L	44.8	55.2	125±22	101.87
G	31.0	69.0	62±18	28.34
F	96.5	3.5	300±52	6500
M2-2	0	0	0	0
P	68.9	31.1	130±24	283.08
M2-1	79.3	20.7	167±21	617.97
N	86.2	13.8	220±33	1178.38

FIG. 18




FIG. 19




FIG. 20



T cell response to PIV-3			
Antigen	(+) %	(-) %	Magnitude SFC/2x10 <sup>5</sup>
HN	88.2	11.8	131 ± 18
Protein C	47	53	214.6 ± 31
PP	47	53	203.7 ± 25
Large	47	53	115.8 ± 16
M	94.1	5.9	261.2 ± 28
N	64.7	35.3	160 ± 19
Fusion	47	53	175.7 ± 26

FIG. 21

T cell response to PIV-3				
Antigen	(+) %	(-) %	Magnitude SFC/2x10 <sup>5</sup>	TC-score rank
HN	88.2	11.8	131 ± 18	2 <sup>nd</sup>
Protein C	47	53	214.6 ± 31	4 <sup>th</sup>
PP	47	53	203.7 ± 25	5 <sup>th</sup>
Large	47	53	115.8 ± 16	7 <sup>th</sup>
M	94.1	5.9	261.2 ± 28	1 <sup>st</sup>
N	64.7	35.3	160 ± 19	3 <sup>rd</sup>
Fusion	47	53	175.7 ± 26	6 <sup>th</sup>

FIG. 22






FIG. 23

Granzyme B					n=13
Antigen	(+) %	(-) %	Magnitude SFC/2x10 <sup>5</sup>	TC-score	
F	12	88	103±27	1113	
M	12	88	42±8	454	
M2-1	10	90	92±18	299	
P	8	92	44±15	70	

FIG. 24




FIG. 25




FIG. 26




FIG. 27




FIG. 28




FIG. 29




FIG. 30






FIG. 31




FIG. 32

# hMPV-T cell manufacture




FIG. 33




FIG. 34




FIG. 35

# Co-culture experiment




FIG. 36

Function: Cytokine production CD4/8




FIG. 37

# Product definition




FIG. 38






FIG. 39




FIG. 40




FIG. 41

Donor Specific




FIG. 42

Off-the-shelf use specific T cells




FIG. 43

Product use

$$HLA_p \text{ vs } HLA_{pt} \geq 1 = 1_{(Th)}$$

$$HLA_p \text{ vs } HLA_{pt} < 1 = 0_{(Th)}$$



Product is given to patient



$$[(R_{TB})+(R_{TK})] \times Th \geq 1 \rightarrow$$

Product is NOT given to patient



$$[(R_{TB})+(R_{TK})] \times Th < 1 \rightarrow$$

FIG. 44




FIG. 45




FIG. 46






FIG. 47

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US16/52487

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - G01N 33/68, 33/50, 33/574; G06F 19/10; A61K 39/00; C12Q 1/68 (2016.01)

CPC - G01N 33/6854, 33/6878, 33/574, 33/5011; A61K 39/0011; G06F 19/3437, 19/34, 19/30; C12Q 1/6886

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC(8): G01N 33/68, 33/50, 33/574; G06F 19/10; A61K 39/00; C12Q 1/68 (2016.01); CPC: G01N 33/6854, 33/6878, 33/574, 2800/52, 33/5011; A61K 39/0011, 2039/5154, 2039/575; G06F 19/3437, 19/34, 19/30; C12Q 1/6886, 2600/136, 2600/156

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

PatSeer (US, EP, WO, JP, DE, GB, CN, FR, KR, ES, AU, IN, CA, INPADOC Data); Google Patent, EBSCO, PubMed  
search terms: immunogenicity, antigen, pathogen, cancer, marker, responder, identify, cytokines, "T cell", 'in vitro', plurality, recognize, expose

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 7,785,806 B2 (WARREN, WL et al.) 21 August 2010; Figure 8; column 5, lines 7-29; column 7, lines 25-52; Claim 1	1-2, 3/1-2, 6-9
Y	US 2002/0051784 A1 (BOUSSIOTIS, VA et al.) 02 May 2002; paragraphs [0100]-[0101]	1-2, 3/1-2, 6-9, 13-19, 21/13-19
Y	US 9,115,402 B2 (HACOHEN, N et al.) 25 August 2015; column 26, lines 1-3	13-17, 21/13-17
Y	(SEIG, S et al.) Infection and Immunoregulation of T Lymphocytes by Parainfluenza Virus Type 3. Proceedings of the National Academy of Sciences of the U. S. A. 5 July 1994, Vol. 91, No. 14; pages 6293-6297; page 6294, column 1, paragraph 5 to column 2, paragraph 1	6-8
Y	(TZANNOU, I et al.) Preventing Stem Cell Transplantation-associated Viral Infections using T-cell Therapy Immunotherapy. Immunotherapy. 7 August 2015, Vol. 7, No. 7; pages 793-810; page 1, paragraph 1 to page 2, paragraph 1; page 6, paragraphs 2-3; page 13, third paragraph; DOI: 10.2217/imt.15.43	6-7, 9
Y	WO 00/50569 A1 (THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY) 31 August 2000; Claims 7, 9-13	18-19, 21/18-19
A	US 2011/0262467 A1 (RILEY, JL et al.) 27 October 2011; Claim 10	20



Further documents are listed in the continuation of Box C.



See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T"

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X"

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y"

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&amp;"

document member of the same patent family

Date of the actual completion of the international search

22 November 2016 (22.11.2016)

Date of mailing of the international search report

19 DEC 2016

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents  
P.O. Box 1450, Alexandria, Virginia 22313-1450  
Facsimile No. 571-273-8300

Authorized officer

Shane Thomas

PCT Helpdesk: 571-272-4300  
PCT OSP: 571-272-7774

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US16/52487

## Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☒ Claims Nos.: 4-5, 10-12, 22-75  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

## 摘要

本公开内容的实施方案涉及用于鉴定来自特定病原体的抗原是否是免疫原性的(包括其免疫原性的级别)的方法。其他实施方案涉及T细胞的属性与其临床效力之间的相关性,例如其数学表示。